

SUPPORTING INFORMATION *for*

A C–H Functionalization Approach to Diverse Nitrogenous Scaffolds Through Conjugate Addition of Catalytic Allyliron Nucleophiles

Sarah G. Scrivener,^a and Yi-Ming Wang^{a*}

^a*Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260*

Contents

General Information	3
1. General procedures	4
2. Characterization data.....	7
2.1 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Maleimides	7
2.1.1 Gram Scale Synthesis.....	14
2.2 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Oxazolidinones	15
2.3 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Phthalimides	18
2.4 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Sulfonamides	26
2.5 Synthesis of Michael acceptor substrates	31
2.5.1 Maleimide Michael Acceptors.....	31
2.5.2 <i>N</i> -Acyl oxazolidinone Michael Acceptors	32
2.5.3 Phthalimide protected Michael Acceptors	32
2.5.4 Sulfonamide protected Michael Acceptors:.....	32
2.6 Synthesis of alkene substrates	34
3. Synthetic applications of products	35
4. Assignment of diastereomers	39
4.1 Assignment for succinimide products 3 by X-ray crystallography	39
4.2 Assignment for β -aminoketones products 7 and 9 by nOe experiments and multiplet analysis	41
4.3 Assignment for oxazolidinone products 5 by chemical correlation with known diol	44
5. Reaction optimization	47
5.1 Optimization of Maleimide Michael Acceptors	47
5.2 Optimization of <i>N</i> -Acyl-Oxazolidinone Michael Acceptors	51
5.3 Optimization of Phthalimide Michael Acceptors	54
5.4 Optimization of Sulfonimide Michael Acceptors	55
6. Unsuccessful substrates.....	56
7. Copies of NMR spectra of products and substrates.....	57
7.1 NMR spectra: Maleimide Scope.....	57
7.2 NMR spectra: Oxazolidinone Scope	106
7.3 NMR spectra: Phthalimide Scope.....	124
7.4 NMR spectra: Sulfonamide Scope.....	167
7.5 NMR spectra of starting materials	183
7.6 NMR spectra of synthetic application of products	191
7.7 Derivatization for <i>N</i> -Acyl oxazolidinone diastereomer assignments	203
8. References.....	206


General Information

General Reagent Information: Anhydrous tetrahydrofuran (THF), 1,2-dichloroethane (DCE), toluene and trifluorotoluene were purchased from Acros (AcroSeal packaging), Sigma Aldrich (Sure/Seal packaging), and Frontier Scientific (J&KSeal packaging), respectively, and were deoxygenated by sparging with nitrogen and transferred into an argon-filled glovebox. Other dry solvents were obtained by distillation and storage over 3Å or 4Å molecular sieves. All other reagents were purchased from Oakwood, Acros, TCI, Strem, Alfa Aesar, or Sigma Aldrich and used as received. 2,2,6,6-Tetramethylpiperidine (TMPH) was purified by short-path vacuum distillation. Cationic iron complex $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ was prepared according to literature procedure.¹ Air sensitive reagents and the iron catalyst (including $\text{BF}_3 \cdot \text{Et}_2\text{O}$, TMPH, silyl triflates, and bistriflimide salts) were stored in the glovebox. Compounds were purified by flash column chromatography using SiliCycle *SiliaFlash*® F60 silica gel, unless otherwise indicated.

General Analytical Information: New compounds were characterized by ^1H NMR, ^{13}C NMR and HRMS. Copies of the ^1H NMR and ^{13}C NMR spectra can be found at the end of the Supporting Information. ^1H and ^{13}C NMR spectra were recorded on Bruker 300 MHz, 400 MHz, or 500 MHz instruments. All ^1H NMR data are reported in δ units, parts per million (ppm), and were measured relative to the residual proton signal in the deuterated solvent at 7.26 ppm (CDCl_3). Throughout analysis of diastereomeric mixtures, H* indicates the major diastereomer, while H' indicates the minor diastereomer. All ^{13}C NMR spectra are ^1H decoupled and reported in ppm relative to the solvent signal at 77.16 ppm (CDCl_3). Thin-layer chromatography (TLC) was performed on Silicycle 250 μm (analytical) or 1000 μm (preparative) silica gel plates. Compounds were visualized by irradiation with UV light, or by staining with potassium permanganate. Yields refer to isolated compounds, unless otherwise indicated. High resolution mass spectra were recorded on a Thermo Scientific Q-Exactive mass spectrometer. NMR yield was determined by using 2,4-dinitrotoluene as internal standard for ^1H spectroscopy.


1. General procedures

General procedure A for the addition of alkenes to maleimide Michael acceptors




A reaction tube (13 mm × 100 mm, Fisherbrand, part # 14-959-35C) equipped with an olive shaped magnetic stir bar (10 mm) was capped with a Teflon/silicone septum (Thermo/National part # C4015-66A) screw cap and flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were added Michael acceptor (**2**, 0.2 mmol, 1.0 equiv), AgNTf_2 (0.07 mmol, 27.7mg, 0.35 equiv), and $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ (20 mol %, 16.8 mg). Dry toluene (0.13 mL, 1.5 M), was added and the solution was briefly stirred. Then alkene (**1**, 0.9 mmol, 3.0 equiv), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.3 mmol, 37 μL , 1.5 equiv), and 4-chloro-2,6-lutidine (0.8 mmol, 103 μL , 4.0 equiv) were sequentially added with brief stirring after each addition. The reaction tube was then removed from the glovebox and placed in an oil bath at 40 °C for 24 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug (2 mL) using ethyl acetate (10 mL). The diastereomeric ratio (d.r.) was then determined by ^1H NMR analysis of a portion of the filtrate. The crude mixture was concentrated *in vacuo*. After concentration *in vacuo*, the crude mixture was purified by flash column chromatography to provide the desired product. The stereochemical outcome was assigned by analogy to the relative configuration of a crystal grown from a diastereomerically-enriched sample of **3fc**. The major diastereomer was determined to be the (R^* , R^*) configuration.

General procedure B for the addition of alkenes to *N*-acyl oxazolidinone Michael acceptors




A reaction tube (13 mm × 100 mm, Fisherbrand, part # 14-959-35C) equipped with an olive shaped magnetic stir bar (10 mm) was capped with a Teflon/silicone septum (Thermo/National part # C4015-66A) screw cap and flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were added Michael acceptor (**4**, 0.2 mmol, 1.0 equiv), LiNTf_2 (0.2 mmol, 57.4 mg, 1.0 equiv), and $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ (20 mol %, 16.8 mg). Dry DCE (0.13 mL, 1.5 M), was added and the solution was briefly stirred. Then alkene (**1**, 0.9 mmol, 3.0 equiv), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (1.0 mmol, 125 μL , 5.0 equiv), and 4-chloro-2,6-lutidine (0.6 mmol, 77 μL , 3.0 equiv) were sequentially added with brief stirring after each addition. The reaction tube was then removed from the glovebox and placed in an oil bath at 80 °C for 24 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug (2 mL) using ethyl acetate (10 mL). The diastereomeric ratio (d.r.) was then determined by ^1H NMR analysis of a portion of the filtrate. The crude mixture was concentrated *in vacuo*. After concentration *in vacuo*, the crude mixture was purified by flash column chromatography to provide the desired product.

General procedure C for the addition of activated alkenes to β -phthalimido Michael acceptors




A reaction tube (13 mm × 100 mm, Fisherbrand, part # 14-959-35C) equipped with an olive shaped magnetic stir bar (10 mm) was capped with a Teflon/silicone septum (Thermo/National part # C4015-66A) screw cap and flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were added Michael acceptor (**6**, 0.3 mmol, 1.0 equiv), LiNTf_2 (0.12 mmol, 34.4 mg, 0.6 equiv), and $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ (20 mol %, 16.8 mg). Dry DCE (0.13 mL, 1.5 M), was added and the solution was briefly stirred. Then alkene (**1**, 0.9 mmol, 3.0 equiv), TIPSOTf (0.5 mmol, 134 μL , 2.5 equiv), and 2,4,6-collidine (0.6 mmol, 75 μL , 3.0 equiv) were sequentially added with brief stirring after each addition. The reaction tube was then removed from the glovebox and placed in an oil bath at 80 °C for 16 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug (2 mL) using ethyl acetate (10 mL). 4N HCl in dioxane (0.4 mmol, 100 μL , 2.0 equiv) was added at room temperature and the mixture was stirred for 30 min at room temperature. The crude mixture was concentrated *in vacuo*. After concentration *in vacuo*, the crude mixture was purified by flash column chromatography to provide the desired product.

General procedure D for the addition of unactivated alkenes to β -phthalimido Michael acceptors



A reaction tube (13 mm × 100 mm, Fisherbrand, part # 14-959-35C) equipped with an olive shaped magnetic stir bar (10 mm) was capped with a Teflon/silicone septum (Thermo/National part # C4015-66A) screw cap and flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were added Michael acceptor (**6**, 0.2 mmol, 1.0 equiv), LiNTf_2 (0.12 mmol, 34.4 mg, 0.6 equiv), and $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ (20 mol %, 16.8 mg). Dry DCE (0.13 mL, 1.5 M), was added and the solution was briefly stirred. Then alkene (**1**, 0.9 mmol, 3.0 equiv), TIPSOTf (0.5 mmol, 134 μL , 2.5 equiv), and TMPH (0.8 mmol, 136 μL , 4.0 equiv) were sequentially added with brief stirring after each addition. The reaction tube was then removed from the glovebox and placed in an oil bath at 80 °C for 16 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug (2 mL) using ethyl acetate (10 mL). 4N HCl in dioxane (0.4 mmol, 100 μL , 2.0 equiv) was added at room temperature and the mixture was stirred for 30 min at room temperature. The crude mixture was concentrated *in vacuo*. After concentration *in vacuo*, the crude mixture was purified by flash column chromatography to provide the desired product.

General procedure E for the addition of alkenes to β -sulfonamido Michael acceptors




A reaction tube (13 mm × 100 mm, Fisherbrand, part # 14-959-35C) equipped with an olive shaped magnetic stir bar (10 mm) was capped with a Teflon/silicone septum (Thermo/National part # C4015-66A) screw cap and flame dried under vacuum and transferred into an argon-filled glovebox. In the

glovebox were added Michael acceptor (**8**, 0.2 mmol, 1.0 equiv), LiNTf₂ (0.12 mmol, 34.4 mg, 0.6 equiv), and [Cp*Fe(CO)₂(thf)]⁺[BF₄]⁻ (20 mol %, 16.8 mg). Dry DCE (0.13 mL, 1.5 M), was added and the solution was briefly stirred. Then alkene (**1**, 0.9 mmol, 3.0 equiv), TIPSOTf (0.5 mmol, 134 μL, 2.5 equiv), and collidine (0.5 mmol, 66 μL, 2.5 equiv) were sequentially added with brief stirring after each addition. The reaction tube was then removed from the glovebox and placed in an oil bath at 60 °C for 18 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug (2 mL) using ethyl acetate (10 mL). 4N HCl in dioxane (0.4 mmol, 100 μL, 2.0 equiv) was added at room temperature and the mixture was stirred for 30 min at room temperature. The crude mixture was concentrated *in vacuo*. After concentration *in vacuo*, the crude mixture was purified by flash column chromatography to provide the desired product.

2. Characterization data

2.1 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Maleimides




1-Benzyl-3-(1-phenylallyl)pyrrolidine-2,5-dione (3aa): (SGS-5-192) Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (54.5 mg, 89%, 7.6:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.27 (m, 1H*+1H'), 7.25 – 7.06 (m, 9H*+9H'), 6.11 (ddd, J = 17.0, 10.4, 6.4 Hz, 1H*), 5.98 – 5.89 (m, 1H'), 5.29 – 5.05 (m, 2H*+2H'), 4.62 (s, 2H'), 4.51 (s, 2H*), 4.14 – 4.06 (m, 1H*), 4.03 – 3.98 (m, 1H'), 3.37 – 3.25 (m, 1H*+1H'), 2.77 – 2.61 (m, 1H*+2H'), 2.51 (dd, J = 18.4, 4.4 Hz, 1H*). Throughout analysis of diastereomeric mixtures, H* indicates the major diastereomer, while H' indicates the minor diastereomer.

¹³C NMR (126 MHz, CDCl₃) δ 178.4, 175.9, 138.2, 138.0, 135.6, 134.8, 129.0₁, 128.9₉, 128.8₅, 128.8, 128.7, 128.6, 128.0, 127.9, 127.8, 127.6, 119.6, 116.6, 49.3, 48.6, 45.3, 44.0, 42.6, 42.4, 31.4, 29.8. Six peaks missing due to overlap and low intensity of minor diastereomer.

HRMS (ESI) calcd for C₂₀H₂₀NO₂ [M+H]⁺: 306.14886, found: 306.14831.




1-Methyl-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ba): (SGS-6-34) Prepared following **General procedure A** using 1-methyl-1*H*-pyrrole-2,5-dione (**2b**, 22.2 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (26.4 mg, 58%, 3.9:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.31 (m, 2H'), 7.31 – 7.19 (m, 3H*+3H'), 7.18 – 7.11 (m, 2H*), 6.15 (ddd, J = 17.1, 10.5, 6.4 Hz, 1H*), 5.99 (ddd, J = 17.0, 10.2, 8.5 Hz, 1H'), 5.29 – 5.10 (m, 2H*+2H'), 4.10 – 4.01 (m, 1H*+1H'), 3.35 – 3.25 (m, 1H*+1H'), 2.95 (s, 3H'), 2.81 (s, 3H*), 2.75 – 2.65 (m, 1H*+2H'), 2.48 (dd, J = 18.3, 4.3 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 178.8, 178.6, 176.5, 176.3, 140.4, 138.4, 137.9, 134.9, 129.0, 128.8, 128.7, 127.8, 127.7, 127.3, 119.6, 116.6, 49.2, 48.8, 45.5, 44.1, 31.5, 31.3, 24.9, 24.7.

HRMS (ESI) calcd for C₁₄H₁₆NO₂ [M+H]⁺: 230.11756, found: 230.11781.




1-(Tert-butyl)-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ca): (SGS-6-35) Prepared following **General procedure A** using 1-(tert-butyl)-1*H*-pyrrole-2,5-dione (**2c**, 30.6 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (37.1 mg, 68%, 6.8:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.14 (m, 5H*+5H'), 6.11 (ddd, J = 17.0, 10.5, 6.2 Hz, 1H*), 5.99 (ddd, J = 17.0, 10.3, 8.5 Hz, 1H'), 5.27 – 5.09 (m, 2H*+2H'), 4.10 – 4.05 (m, 1H*), 4.01 (dd, J = 8.4, 3.9 Hz, 1H'), 3.18 – 3.08 (m, 1H*+1H'), 2.64 – 2.50 (m, 1H*+2H'), 2.41 (dd, J = 18.2, 4.3 Hz, 1H*), 1.54 (s, 9H'), 1.38 (s, 9H*).

¹³C NMR (126 MHz, CDCl₃) δ 179.9, 179.7, 177.6, 177.4, 140.7, 138.3, 138.2, 134.9, 129.0, 128.9, 128.8, 127.8, 127.6, 127.2, 119.5, 116.4, 58.6, 58.4, 49.5, 48.9, 45.0, 43.8, 31.9, 31.7, 28.5, 28.3.

HRMS (ESI) calcd for C₁₇H₂₂NO₂ [M+H]⁺: 272.16451, found: 272.16487.




1-Cyclohexyl-3-(1-phenylallyl)pyrrolidine-2,5-dione (3da): (SGS-6-24) Prepared following **General procedure A** using 1-cyclohexyl-1*H*-pyrrole-2,5-dione (**2d**, 35.8 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (40.9 mg, 82%, 6.8:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.12 (m, 5H*+5H'), 6.12 (ddd, J = 17.0, 10.5, 6.2 Hz, 1H*), 5.98 (ddd, J = 17.0, 10.2, 8.5 Hz, 1H'), 5.28 – 5.09 (m, 2H*+2H'), 4.15 – 4.08 (m, 1H*), 4.02 (dd, J = 8.5, 3.9 Hz, 1H'), 3.94 (tt, J = 12.4, 3.9 Hz, 1H'), 3.78 (tt, J = 12.4, 3.8 Hz, 1H*), 3.26 – 3.15 (m, 1H*+1H'), 2.70 – 2.61 (m, 1H*+1H'), 2.58 (dd, J = 18.4, 4.7 Hz, 1H'), 2.45 (dd, J = 18.4, 4.1 Hz, 1H*), 2.17 – 1.49 (m, 6H*+6H'), 1.34 – 1.08 (m, 4H*+4H').

¹³C NMR (126 MHz, CDCl₃) δ 178.9, 178.7, 176.6, 176.4, 140.6, 138.2, 138.0, 134.8, 128.9, 128.8, 127.8, 127.6, 127.2, 119.5, 116.4, 51.9, 51.7, 49.3, 48.7, 44.8, 43.4, 31.2, 31.1, 29.0, 28.8, 28.7, 28.6, 26.0, 25.9, 25.2, 25.1. Three peaks missing due to overlap.

HRMS (ESI) calcd for C₁₉H₂₄NO₂ [M+H]⁺: 298.18016, found: 298.18073.




1-Cyclobutyl-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ea) (SGS-6-44) Prepared following **General procedure A** using 1-cyclobutyl-1*H*-pyrrole-2,5-dione (**2e**, 30.2 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (45.4 mg, 84%, 6.1:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.11 (m, 5H*+5H'), 6.13 (ddd, *J* = 16.9, 10.5, 6.2 Hz, 1H*), 5.98 (ddd, *J* = 17.1, 10.2, 8.6 Hz, 1H'), 5.32 – 5.06 (m, 2H*+2H'), 4.55 (p, *J* = 9.0 Hz, 1H'), 4.40 (p, *J* = 8.9 Hz, 1H*), 4.11 – 4.04 (m, 1H*), 4.01 (dd, *J* = 8.3, 3.9 Hz, 1H'), 3.28 – 3.14 (m, 1H*+1H'), 2.86 – 2.75 (m, 2H'), 2.73 – 2.52 (m, 3H*+2H'), 2.43 (dd, *J* = 18.3, 4.1 Hz, 1H*), 2.15 – 2.06 (m, 2H'), 2.03 – 1.93 (m, 2H*+1H'), 1.90 – 1.56 (m, 2H*+2H').

¹³C NMR (126 MHz, CDCl₃) δ 179.1, 178.8, 176.6, 176.4, 140.5, 138.2, 138.0, 135.0, 128.9, 128.8, 127.8, 127.6, 127.3, 119.4, 116.5, 49.4, 48.8, 45.5, 45.3, 44.8, 43.5, 31.3, 26.6, 26.5, 26.3, 15.5, 15.4. Three peaks missing due to overlap.

HRMS (ESI) calcd for C₁₇H₂₀NO₂ [M+H]⁺: 270.14886, found: 270.14832.




1-Phenyl-3-(1-phenylallyl)pyrrolidine-2,5-dione (3fa): (SGS-6-27) Prepared following **General procedure A** using 1-phenyl-1*H*-pyrrole-2,5-dione (**2f**, 34.6 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (44.1 mg, 75%, 3.8:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.45 (t, *J* = 7.7 Hz, 2H'), 7.42 – 7.16 (m, 8H*+8H'), 6.94 (d, *J* = 7.6 Hz, 2H*), 6.22 – 6.09 (m, 1H*+1H'), 5.36 – 5.10 (m, 2H*+2H'), 4.27 – 4.22 (m, 1H*), 4.13 (dd, *J* = 8.6, 3.8 Hz, 1H'), 3.56 – 3.42 (m, 1H*+1H'), 2.95 – 2.77 (m, 1H*+2H'), 2.71 (dd, *J* = 18.5, 4.0 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 177.9, 177.6, 175.4, 175.3, 140.2, 138.0, 137.7, 134.8, 132.0, 131.8, 129.3, 129.2, 129.1, 129.0, 128.8, 128.8, 127.9, 127.8, 127.5, 126.6, 126.2, 119.9, 116.8, 49.6, 48.8, 45.5, 44.1, 31.5, 31.4. One peak missing due to overlap.

HRMS (ESI) calcd for C₁₉H₁₈NO₂ [M+H]⁺: 292.13321, found: 292.13279.




1-(1-(2,6-Dimethylphenoxy)propan-2-yl)-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ga): (SGS-6-65) Prepared following **General procedure A** using 1-(1-(2,6-dimethylphenoxy)propan-2-yl)-1*H*-pyrrole-2,5-dione (**2g**, 51.8 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (57.3

mg, 76%, 5.3:1 d.r. with respect to the newly generated stereocenters, d.r. with respect to the stereocenter designated by * could not be determined by ¹H NMR due to extensive signal overlap).

¹H NMR (601 MHz, CDCl₃) δ 7.37 – 7.11 (m, 5H*+5H'), 7.00 – 6.94 (m, 2H*+2H'), 6.92 – 6.87 (m, 1H*+1H'), 6.20 – 6.09 (m, 1H*), 6.07 – 5.97 (m, 1H'), 5.30 – 5.11 (m, 2H*+2H'), 4.74 – 4.67 (m, 1H'), 4.59 – 4.51 (m, 1H*), 4.30 (t, *J* = 9.3 Hz, 1H'), 4.16 – 4.04 (m, 2H*+1H'), 3.81 – 3.75 (m, 1H'), 3.75 – 3.66 (m, 1H*), 3.37 – 3.23 (m, 1H*+1H'), 2.78 – 2.66 (m, 1H*+2H'), 2.56 – 2.47 (m, 1H*), 2.23 (s, 3H'), 2.21 (s, 3H'), 2.19 (s, 3H*), 2.15 (s, 3H*), 1.40 – 1.25 (m, 3H'), 1.24 – 1.13 (m, 3H*).

¹³C NMR (151 MHz, CDCl₃) δ 178.9, 178.7, 178.5, 176.6, 176.5, 176.4, 176.3, 155.5, 155.4, 155.2₉, 155.2₅, 140.6, 140.5, 138.5, 138.2, 138.0₂, 137.9₉, 135.0₇, 134.9₅, 130.8₈, 130.8₄, 130.8₀, 128.9₇, 128.9₅, 128.9₀, 128.8₅, 128.8₅, 128.7₇, 127.9, 127.8, 127.7, 127.6, 127.3, 124.0₉, 124.0₇, 124.0₅, 119.6₂, 119.5₆, 116.6, 116.5, 71.0₃, 70.9₆, 70.9, 70.7, 49.2₇, 49.2₅, 49.0, 48.6, 48.1, 48.0, 47.9, 47.8, 45.0, 44.9, 43.7, 43.6, 31.5, 31.4, 31.3, 31.2, 16.5, 16.4₃, 16.3₅, 16.3, 14.4, 14.3₄, 14.3₀, 14.2. (Complexity due to diastereomers originating from the stereocenter indicated by *)

HRMS (ESI) calcd for C₂₄H₂₈NO₃ [M+H]⁺: 378.20637, found: 378.20631.



3-(1-Phenylallyl)-1-(4-(trifluoromethyl)benzyl)pyrrolidine-2,5-dione (3ha): (SGS-6-40)


Prepared following **General procedure A** using 1-(4-(trifluoromethyl)benzyl)-1*H*-pyrrole-2,5-dione (**2h**, 51.0 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a brown oil (48.8 mg, 65%, 7.0:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.57 – 7.42 (m, 2H*+2H'), 7.22 – 7.03 (m, 7H*+7H'), 6.10 (ddd, *J* = 17.0, 10.5, 6.2 Hz, 1H*), 5.96 (ddd, *J* = 17.1, 10.2, 8.6 Hz, 1H'), 5.31 – 5.06 (m, 2H*+2H'), 4.66 (s, 2H'), 4.54 (s, 2H*), 4.13 (dd, *J* = 6.0, 4.6 Hz, 1H*), 3.99 (dd, *J* = 8.1, 4.4 Hz, 1H'), 3.37 (dt, *J* = 9.0, 4.4 Hz, 1H*), 3.31 (dt, *J* = 9.0, 4.5 Hz, 1H'), 2.82 – 2.54 (m, 2H*+2H').

¹³C NMR (151 MHz, CDCl₃) δ 178.3, 178.0, 175.9, 175.8, 140.2, 139.6, 139.4, 137.8, 137.8, 134.8, 130.12 (q, *J* = 32.3 Hz), 129.3, 129.0, 128.9, 128.8₂, 128.8₁, 127.8, 127.7, 127.4, 125.65 (q, *J* = 4.0 Hz), 124.16 (q, *J* = 272.1 Hz), 119.6, 116.6, 49.4, 48.4, 45.3, 43.9, 42.0, 41.8, 31.4, 31.2. Three peaks missing due to overlap.

¹⁹F NMR (471 MHz, CDCl₃) δ –62.66, –62.67.

HRMS (ESI) calcd for C₂₁H₁₉NO₂F₃ [M+H]⁺: 374.13624, found: 374.13661.



3-(1-Phenylallyl)-1-(4-(trifluoromethyl)phenyl)pyrrolidine-2,5-dione (3ia): (SGS-6-59) Prepared following **General procedure A** using 1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dione (**2i**, 48.2 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated


at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 5:1) to afford the title compound as a brown oil (60.0 mg, 84%, 3.5:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, *J* = 8.2 Hz, 2H'), 7.66 (d, *J* = 8.2 Hz, 2H*), 7.41 – 7.24 (m, 3H*+8H'), 7.21 (d, *J* = 7.3 Hz, 2H*), 7.11 (d, *J* = 8.2 Hz, 2H*), 6.26 – 6.07 (m, 1H*+1H'), 5.41 – 5.14 (m, 2H*+2H'), 4.24 (s, 1H*), 4.13 (dd, *J* = 8.6, 3.7 Hz, 1H'), 3.59 – 3.45 (m, 1H*+1H'), 2.98 – 2.88 (m, 1H*+1H'), 2.84 (dd, *J* = 18.6, 4.5 Hz, 1H'), 2.76 (dd, *J* = 18.6, 3.8 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 177.5, 177.1, 174.9, 174.7, 139.9, 137.8, 137.5, 135.0, 134.9, 134.7, 130.7₁ (q, *J* = 33.2 Hz), 130.6₈ (q, *J* = 33.0 Hz), 129.1, 129.0, 128.9, 128.0, 127.8, 127.6, 126.8₄, 126.8₀, 126.4 – 126.2 (m), 123.8₀ (q, *J* = 271.9 Hz), 123.7₇ (q, *J* = 272.4 Hz), 120.0, 117.0, 49.7, 48.8, 45.5, 44.2, 31.6, 31.4.

¹⁹F NMR (471 MHz, CDCl₃) δ –62.75, –62.78.

HRMS (ESI) calcd for C₂₀H₁₇NO₂F₃ [M+H]⁺: 360.12059, found: 360.11995.




1-(4-Bromophenyl)-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ja): (SGS-6-22) Prepared following **General procedure A** using 1-(4-bromophenyl)-1*H*-pyrrole-2,5-dione (**2j**, 50.4 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a brown solid (52.0 mg, 70%, 3.4:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.60 – 7.57 (m, 2H'), 7.55 – 7.49 (m, 2H*), 7.39 – 7.27 (m, 3H*+6H'), 7.23 – 7.19 (m, 2H*), 7.13 – 7.09 (m, 2H'), 6.87 – 6.82 (m, 2H*), 6.23 – 6.08 (m, 1H*+1H'), 5.37 – 5.16 (m, 2H*+2H'), 4.23 (dd, *J* = 5.7, 4.5 Hz, 1H*), 4.12 (dd, *J* = 8.6, 3.8 Hz, 1H'), 3.53 – 3.48 (m, 1H*), 3.48 – 3.43 (m, 1H'), 2.95 – 2.86 (m, 1H*+1H'), 2.82 (dd, *J* = 18.6, 4.6 Hz, 1H'), 2.73 (dd, *J* = 18.6, 3.9 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 177.6, 177.2, 175.0, 174.9, 137.9, 137.6, 134.7, 132.5, 132.4, 130.8, 129.1, 129.0, 128.9, 128.1₀, 128.0₈, 128.0, 127.8, 127.6, 122.7, 120.0, 116.9, 49.7, 48.8, 45.5, 44.2, 31.6, 31.4. Three peaks missing due to overlap and low intensity of minor diastereomer.

HRMS (ESI) calcd for C₁₉H₁₅NO₂Br [M+H]⁺: 368.02807, found: 368.02870.

m.p. = 98 – 100 °C




1-(4-Methoxyphenyl)-3-(1-phenylallyl)pyrrolidine-2,5-dione (3ka): (SGS-6-38) Prepared following **General procedure A** using 1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dione (**2k**, 40.1 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (43.7 mg, 68%, 3.4:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.20 (m, 5H*+5H'), 7.13 – 7.08 (m, 2H'), 6.98 – 6.04 (m, 2H'), 6.92 – 6.87 (m, 2H*), 6.87 – 6.82 (m, 2H*), 6.22 – 6.08 (m, 1H+1H'), 5.34 – 5.15 (m, 2H*+2H'), 4.26 – 4.20 (m, 1H*), 4.14 – 4.09 (m, 1H'), 3.81 (s, 3H'), 3.78 (s, 3H*), 3.51 – 3.40 (m, 1H*+1H'), 2.93 – 2.83 (m, 1H*+1H'), 2.79 (dd, *J* = 18.5, 4.6 Hz, 1H'), 2.69 (dd, *J* = 18.5, 4.0 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 178.2, 177.8, 175.7, 175.5, 159.6₈, 159.6₅, 140.2, 138.0, 137.7, 134.8, 129.0, 129.0, 128.9, 127.9, 127.8, 127.4, 124.6, 124.4, 119.8, 116.7, 114.6₂, 114.5₆, 55.6₀, 55.5₆, 49.6, 48.7, 45.4, 44.1, 31.5, 31.3. One peak missing due to overlap.

HRMS (ESI) calcd for C₂₀H₂₀NO₃ [M+H]⁺: 322.14377, found: 322.14390.



1-Benzyl-3-(1-(4-fluorophenyl)allyl)pyrrolidine-2,5-dione (3ab): (SGS-6-56)


Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and 4-fluoroallylbenzene (**1b**, 81 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a brown oil (46.1 mg, 71%, 6.5:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.27 – 7.21 (m, 3H*+5H'), 7.16 – 7.10 (m, 2H*+2H'), 7.05 – 6.99 (m, 2H*), 6.96 (t, *J* = 8.6 Hz, 2H'), 6.81 (t, *J* = 8.6 Hz, 2H*), 6.05 (ddd, *J* = 17.0, 10.5, 6.2 Hz, 1H*), 5.92 (ddd, *J* = 17.0, 10.3, 8.4 Hz, 1H'), 5.29 – 5.04 (m, 2H*+2H'), 4.64 – 4.45 (m, 2H*+2H'), 4.11 (dd, *J* = 5.7, 4.5 Hz, 1H*), 3.95 (dd, *J* = 8.2, 4.3 Hz, 1H'), 3.31 (dt, *J* = 8.9, 4.3 Hz, 1H*), 3.24 (dt, *J* = 9.0, 4.5 Hz, 1H'), 2.79 – 2.69 2.60 (m, 1H*+1H'), (dd, *J* = 18.4, 4.6 Hz, 1H'), 2.48 (dd, *J* = 18.5, 4.4 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 178.3, 175.8, 162.1 (d, *J* = 246.3 Hz), 137.6, 135.6, 135.0, 133.7 (d, *J* = 3.2 Hz), 130.3 (d, *J* = 8.1 Hz), 129.3 (d, *J* = 8.2 Hz), 129.0, 128.7 (d, *J* = 3.0 Hz), 128.1, 128.0, 119.5, 116.8, 115.9, 115.8, 115.6, 48.8, 47.6, 46.1, 45.2, 43.8, 42.4, 31.5, 31.1. Four peaks missing due to overlap.

¹⁹F NMR (471 MHz, CDCl₃) δ -114.83, -115.33.

HRMS (ESI) calcd for C₂₀H₁₉NO₂F [M+H]⁺: 324.13943, found: 324.13974.




1-Benzyl-3-(1-(4-methoxyphenyl)allyl)pyrrolidine-2,5-dione (3ac) (SGS-6-46) Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and 4-methoxyallylbenzene (**1i**, 92 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (60.8 mg, 90%, 6.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.10 (m, 5H*+5H'), 7.07 (d, *J* = 8.5 Hz, 2H'), 6.99 (d, *J* = 8.4 Hz, 2H*), 6.81 (d, *J* = 8.5 Hz, 2H'), 6.68 (d, *J* = 8.5 Hz, 2H*), 6.08 (ddd, *J* = 16.9, 10.4, 6.1 Hz, 1H*), 5.98 – 5.89 (m, 1H'), 5.29 – 5.02 (m, 2H*+2H'), 4.62 (s, 2H'), 4.51 (s, 2H*), 4.12 – 4.07 (m, 1H*), 3.93 (dd, *J*

= 7.6, 3.9 Hz, 1H'), 3.78 (s, 3H'), 3.75 (s, 3H*), 3.35 – 3.22 (m, 1H*+1H'), 2.77 – 2.59 (m, 1H*+2H'), 2.51 (dd, $J = 18.4, 4.3$ Hz, 1H*).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 178.6, 178.2, 176.0, 158.9, 158.7, 138.3, 135.8, 135.6, 135.4, 132.2, 129.9, 129.8, 129.0, 128.8, 128.7, 128.6, 128.0, 127.8, 119.1, 116.2, 114.3, 114.2, 55.4, 55.3, 48.7, 47.6, 45.4, 44.0, 42.5, 42.3, 31.5, 31.2. One peak missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_3$ $[\text{M}+\text{H}]^+$: 336.15942, found: 336.15950.




4-(1-(1-Benzyl-2,5-dioxopyrrolidin-3-yl)allyl)phenyl trifluoromethanesulfonate (3ad): (SGS-6-54) Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and 4-allylphenyl trifluoromethanesulfonate (**1d**, 159.7 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a brown oil (65.5 mg, 72%, 5.0:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.36 – 7.13 (m, 7H*+9H'), 7.02 (d, $J = 8.6$ Hz, 2H*), 6.07 – 5.98 (m, 1H*), 5.95 – 5.82 (m, 1H'), 5.36 – 5.06 (m, 2H*+2H'), 4.62 (s, 2H'), 4.52 (q, $J = 14.0$ Hz, 2H*), 4.14 – 4.09 (m, 1H*), 4.01 (dd, $J = 8.1, 4.3$ Hz, 1H'), 3.34 (dt, $J = 8.9, 4.3$ Hz, 1H*), 3.26 (dt, $J = 9.1, 4.5$ Hz, 1H'), 2.83 – 2.70 (m, 1H*+1H'), 2.60 (dd, $J = 18.4, 4.5$ Hz, 1H'), 2.43 (dd, $J = 18.4, 4.4$ Hz, 1H*).

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 178.0, 177.6, 175.5, 175.4, 148.7, 148.6, 141.0, 138.8, 136.7, 135.7, 135.6, 134.1, 130.6, 129.6, 129.1, 128.9, 128.8, 128.7, 128.2, 128.1, 121.9, 121.6, 120.3, 119.9, 48.8, 47.9, 44.9, 43.6, 42.7, 42.5, 31.4, 31.3.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -72.85, -72.93.

HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_5\text{SF}_3$ $[\text{M}+\text{H}]^+$: 454.09305, found: 454.09191.




3-(1-(Benzo[*d*][1,3]dioxol-5-yl)allyl)-1-benzylpyrrolidine-2,5-dione (3ae): (SGS-6-45) Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and safrole (**1e**, 89 μL , 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (50.9 mg, 72%, 7.4:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.38 – 7.13 (m, 5H*+5H'), 6.74 – 6.49 (m, 3H*+3H'), 6.05 (ddd, $J = 16.9, 10.4, 6.2$ Hz, 1H*), 5.92 (d, $J = 14.2$ Hz, 2H*+3H'), 5.27 – 5.03 (m, 1H*+1H'), 4.66 – 4.58 (m, 2H'), 4.57 – 4.09 (m, 2H*), 4.08 – 4.01 (s, 1H*), 3.89 (dd, $J = 7.8, 3.8$ Hz, 1H'), 3.29 (dt, $J = 8.6, 4.1$ Hz, 1H*), 3.22 (dt, $J = 8.6, 4.2$ Hz, 1H'), 2.72 (dt, $J = 14.4, 7.2$ Hz, 1H*+1H'), 2.62 (dd, $J = 18.6, 4.3$ Hz, 1H'), 2.52 (dd, $J = 18.5, 4.3$ Hz, 1H*).

^{13}C NMR (126 MHz, CDCl_3) δ 178.4, 178.0, 176.0, 148.1, 147.9, 146.9, 146.7, 138.0, 135.8, 135.6, 135.1, 134.1, 131.8, 128.9, 128.6₄, 128.6₀, 128.6, 128.0, 127.8, 122.1, 120.8, 119.3, 116.3, 109.1, 108.6, 108.5, 108.2, 101.2, 49.1, 48.0, 45.4, 44.0, 42.5, 42.4, 31.4, 31.2.

HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{20}\text{NO}_4$ $[\text{M}+\text{H}]^+$: 350.13868, found: 350.13750.



4-(1-(1-Benzyl-2,5-dioxopyrrolidin-3-yl)allyl)-2-methoxyphenyl benzoate (3af): (SGS-6-55)

Prepared following **General procedure A** using 1-benzyl-1*H*-pyrrole-2,5-dione (**2a**, 37.4 mg, 0.2 mmol, 1.0 equiv) and 2-methoxy-4-(6-oxo-4,6-diphenylhex-1-en-3-yl)phenyl benzoate (**1f**, 160.9 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 40 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a yellow oil (75.2 mg, 83%, 8.5:1 d.r.).


^1H NMR (500 MHz, CDCl_3) δ 8.22 – 8.18 (m, 2H*+2H'), 7.65 – 7.60 (m, 1H*+1H'), 7.54 – 7.47 (m, 2H*+2H'), 7.36 – 7.20 (m, 3H*+4H'), 7.15 – 7.10 (m, 2H*+1H'), 7.07 (d, J = 8.1 Hz, 1H'), 6.98 (d, J = 8.1 Hz, 1H*), 6.83 – 6.69 (m, 2H*+2H'), 6.10 (ddd, J = 17.0, 10.5, 6.3 Hz, 1H*), 5.91 (ddd, J = 17.1, 10.2, 8.6 Hz, 1H'), 5.30 – 5.07 (m, 2H*+2H'), 4.65 – 4.48 (m, 2H*+2H'), 4.11 (s, 1H*), 4.05 (dd, J = 8.4, 3.6 Hz, 1H'), 3.75 (s, 3H'), 3.62 (s, 3H*), 3.38 – 3.31 (m, 1H*), 3.31 – 3.25 (m, 1H'), 2.82 – 2.65 (m, 1H*+2H'), 2.57 (dd, J = 18.4, 4.7 Hz, 1H*).

^{13}C NMR (126 MHz, CDCl_3) δ 178.3, 178.1, 176.0, 175.8, 164.8, 164.6, 151.6, 151.4, 139.4, 139.3, 139.1, 137.6, 137.1, 135.7, 135.5, 134.2, 133.6, 130.4, 129.5, 128.9, 128.6₉, 128.6₅, 128.3, 128.0, 127.9, 123.2, 123.1, 120.7, 120.0, 119.6, 116.7, 113.3, 112.3, 56.0, 55.9, 48.9, 48.3, 45.5, 43.9, 42.6, 42.4, 31.5, 31.2. Three peaks missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{26}\text{NO}_5$ $[\text{M}+\text{H}]^+$: 456.18055, found: 456.17893.

2.1.1 Gram Scale Synthesis

1 mmol scale synthesis of 3-(1-(4-methoxyphenyl)allyl)-1-phenylpyrrolidine-2,5-dione (3fc) (SGS-6-47)



1 mmol scale reaction: A 25 mL round bottom flask equipped with a magnetic stir bar and septa was flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were sequentially added $[\text{Cp}^*\text{Fe}(\text{CO})_2(\text{thf})]^+[\text{BF}_4]^-$ (20 mol %, 82.2 mg), $\text{Mg}(\text{NTf}_2)_2$ (204.6 mg, 0.35 equiv), 1-phenyl-1*H*-pyrrole-2,5-dione (**2f**, 173.2 mg, 1.0 mmol, 1.0 equiv), and dry toluene (0.65 mL, 1.5 M). The solution was briefly stirred. Then 4-allylanisole (**1c**, 0.46 mL, 3.0 equiv), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (186 μL , 1.5 equiv), and 4-Cl-lutidine (0.52 mL, 4.0 equiv) were sequentially added with brief stirring after each addition. The flask was

then sealed and removed from the glovebox and placed in an oil bath at 40 °C for 24 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug using ethyl acetate. The crude mixture was concentrated *in vacuo*. The crude mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a brown oil (311.0 mg, 96%, 4.9:1 isolated d.r.). Succinimide **3fc** was crystallized from a diastereomerically enriched sample and relative stereochemistry was assigned through X-ray diffraction.


¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.26 (m, 3H*+3H'), 7.21 – 7.07 (m, 2H*+4H'), 6.96 (d, J = 7.6 Hz, 2H*), 6.89 – 6.79 (m, 2H*+2H'), 6.18 – 6.03 (m, 1H*+1H'), 5.32 – 5.07 (m, 2H*+2H'), 4.22 – 4.14 (m, 1H*), 4.03 (dd, J = 8.4, 3.7 Hz, 1H'), 3.76 (s, 3H'), 3.74 (s, 3H*), 3.44 – 3.39 (m, 1H*), 3.38 – 3.34 (m, 1H'), 2.89 – 2.78 (m, 1H*+1H'), 2.74 (dd, J = 18.5, 4.4 Hz, 1H'), 2.65 (dd, J = 18.5, 3.9 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 178.0, 177.5, 175.4, 175.2, 159.1, 158.7, 137.9, 135.2, 132.0, 131.9, 131.8, 129.9, 129.7, 129.1₂, 129.0₆, 128.7, 128.6₁, 128.5₈, 126.5, 119.3, 116.3, 114.3, 114.2, 55.3, 48.8, 47.7, 45.4, 44.0, 31.5, 31.2. One peak missing due to overlap.

HRMS (ESI) calcd for C₂₀H₂₀NO₃ [M+H]⁺: 322.14377, found: 322.14220.

m.p. = 93 – 97 °C


3 mmol scale synthesis of 1-(4-Bromophenyl)-3-(1-phenylallyl)pyrrolidine-2,5-dione (**3ka**) (SGS-6-82)



3 mmol scale reaction: A 25 mL round bottom flask equipped with a magnetic stir bar and septa was flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were sequentially added [Cp*Fe(CO)₂(thf)]⁺[BF₄]⁻ (20 mol %, 246.6 mg), Mg(NTf₂)₂ (613.8 mg, 0.35 equiv), 1-(4-bromophenyl)-1H-pyrrole-2,5-dione (**2k**, 752.9 mg, 3.0 mmol, 1.0 equiv), and dry toluene (2.0 mL, 1.5 M). The solution was briefly stirred. Then allylbenzene (**1a**, 1.19 mL, 3.0 equiv), BF₃·Et₂O (558 μL, 1.5 equiv), and 4-Cl-lutidine (1.56 mL, 4.0 equiv) were sequentially added with brief stirring after each addition. The flask was then sealed and removed from the glovebox and placed in an oil bath at 40 °C for 24 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug using ethyl acetate. The crude mixture was concentrated *in vacuo*. The crude mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a brown oil (1.0224 g, 92%, 4.0:1 d.r.).

Characterization data match that of 0.2 mmol scale synthesis entry for **3ka**.

2.2 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Oxazolidinones




3-(3,4-Diphenylhex-5-enoyl)oxazolidin-2-one (5aa): (SGS-6-21) Prepared following **General procedure B** using 3-cinnamoyloxazolidin-2-one (**4a**, 43.4 mg, 0.2 mmol, 1.0 equiv) and allylbenzene

(**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 3:1) to afford the title compound as a brown oil (58.8 mg, 88%, 2.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 6.97 (m, 10H* + 10H'), 6.09 (dt, J = 17.0, 9.8 Hz, 1H'), 5.79 (ddd, J = 17.1, 10.2, 8.1 Hz, 1H*), 5.13 (dd, J = 17.0, 1.1 Hz, 1H'), 5.03 (dd, J = 10.0, 1.6 Hz, 1H'), 4.75 (ddd, J = 10.3, 1.5, 0.7 Hz, 1H*), 4.70 – 4.61 (m, 1H*), 4.30 (td, J = 9.0, 6.7 Hz, 1H'), 4.26 – 4.09 (m, 2H* + 1H'), 3.89 – 3.76 (m, 2H'), 3.73 – 3.62 (m, 3H* + 1H'), 3.60 – 3.48 (m, 1H* + 2H'), 3.46 – 3.34 (m, 1H* + 1H'), 3.01 (dd, J = 16.8, 4.8 Hz, 1H*). Throughout analysis of diastereomeric mixtures, H* indicates the major diastereomer, while H' indicates the minor diastereomer.

¹³C NMR (126 MHz, CDCl₃) δ 172.4, 172.1, 153.9, 153.4, 142.51, 142.46, 142.4, 142.1, 140.3, 139.8, 128.8, 128.6, 128.5, 128.4, 128.3, 128.0, 126.80, 126.75, 126.4, 126.2, 116.6, 116.2, 62.0, 61.9, 57.3, 56.1, 46.9, 46.5, 42.6, 42.5, 39.71, 39.68.

HRMS (ESI) calcd for C₂₁H₂₂O₃N [M+H]⁺: 336.15942, found: 336.15835.




3-(3-(4-Chlorophenyl)-4-phenylhex-5-enoyl)oxazolidin-2-one (5ba): (SGS-6-71). Prepared following **General procedure B** using 3-(3-(4-chlorophenyl)acryloyl)oxazolidin-2-one (**4b**, 43.4 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 3:1) to afford the title compound as a yellow foam (55.2 mg, 75%, 2.3:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.30 (m, 2H*), 7.28 – 7.21 (m, 3H* + 4H'), 7.19 – 7.11 (m, 2H* + 2H'), 7.10 – 7.03 (m, 1H* + 1H'), 7.02 – 6.97 (m, 1H* + 2H'), 6.07 (dt, J = 17.0, 9.8 Hz, 1H'), 5.78 (ddd, J = 17.1, 10.2, 8.4 Hz, 1H*), 5.21 (d, J = 16.9 Hz, 1H'), 5.12 (dd, J = 10.1, 1.3 Hz, 1H'), 4.86 (d, J = 10.3 Hz, 1H*), 4.76 (d, J = 17.0 Hz, 1H*), 5.25 – 5.10 (m, 2H'), 4.81 (dd, J = 47.8, 13.6 Hz, 2H*), 4.35 – 4.18 (m, 2H* + 2H'), 3.91 – 3.78 (m, 1H*), 3.72 (td, J = 7.9, 2.0 Hz, 1H* + 2H'), 3.69 – 3.62 (m, 1H* + 1H'), 3.57 – 3.35 (m, 2H* + 3H'), 2.99 (dd, J = 17.1, 4.7 Hz, 1H*).

¹³C NMR (126 MHz, CDCl₃) δ 172.0, 171.7, 153.5, 153.3, 142.0₄, 142.0₂, 140.8, 140.6, 139.9, 139.3, 132.3, 131.9, 130.0, 129.7, 128.7, 128.3₉, 128.3₅, 128.1, 127.9, 126.8, 126.3, 116.8, 116.5, 62.0, 61.8, 57.1, 55.9, 46.1, 45.7, 42.5, 42.4, 39.4₉, 39.4₅. One peak missing due to overlap.

HRMS (ESI) calcd for C₂₁H₂₁NO₃Cl [M+H]⁺: 370.12045, found: 370.12052.




3-(4-(2-Bromophenyl)-3-(4-chlorophenyl)hex-5-enoyl)oxazolidin-2-one (5bg): (SGS-6-77) Prepared following **General procedure B** using 3-(3-(4-chlorophenyl)acryloyl)oxazolidin-2-one (**4b**, 43.4 mg, 0.2 mmol, 1.0 equiv) and 2-bromoallylbenzene (**1g**, 89 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 24 h. The crude reaction mixture was purified by flash column

chromatography (hexanes/ethyl acetate = 3:1) to afford the title compound as a yellow foam (76.5 mg, 85%, 2.3:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.59 (dd, *J* = 8.0, 1.1 Hz, 1H^{*}), 7.36 (dd, *J* = 8.0, 1.0 Hz, 1H¹), 7.30 – 7.21 (m, 3H^{*}+2H¹), 7.20 – 7.13 (m, 2H^{*}+3H¹), 7.12 – 7.06 (m, 2H^{*}+1H¹), 6.90 (td, *J* = 8.0, 1.6 Hz, 1H¹), 5.92 (dt, *J* = 17.0, 9.7 Hz, 1H¹), 5.72 (ddd, *J* = 17.1, 10.2, 8.3 Hz, 1H^{*}), 5.23 (d, *J* = 16.6 Hz, 1H¹), 5.07 (dd, *J* = 10.0, 1.2 Hz, 1H¹), 4.84 (d, *J* = 10.2 Hz, 1H^{*}), 4.78 (d, *J* = 17.0 Hz, 1H^{*}), 4.36 – 4.18 (m, 3H^{*}+3H¹), 3.92 – 3.79 (m, 2H¹), 3.79 – 3.72 (m, 2H^{*}+1H¹), 3.67 (td, *J* = 10.1, 4.0 Hz, 1H^{*}), 3.50 (dd, *J* = 16.7, 10.4 Hz, 1H^{*}), 3.43 (dd, *J* = 17.2, 9.5 Hz, 1H¹), 3.35 (dd, *J* = 17.2, 4.5 Hz, 1H¹), 2.85 (dd, *J* = 16.7, 4.0 Hz, 1H^{*}).

¹³C NMR (126 MHz, CDCl₃) δ 171.9, 171.6, 153.6, 153.4, 141.1₁, 141.0₅, 140.3, 138.7, 137.8, 133.4, 133.1, 132.6, 132.2, 130.2, 129.9, 129.2, 128.9, 128.6, 128.3, 128.2, 127.8₃, 127.8₁, 127.5, 125.5, 124.8, 117.9, 117.6, 62.1, 62.0, 53.9, 53.3, 45.7, 44.7, 42.6, 42.5, 39.8, 39.2. One peak missing due to overlap.

HRMS (ESI) calcd for C₂₁H₂₀NO₃ClBr [M+H]⁺: 448.03096, found: 448.03139.



2-Methoxy-4-(6-oxo-6-(2-oxooxazolidin-3-yl)-4-phenylhex-1-en-3-yl)phenyl 4-(*N,N*-dipropylsulfamoyl)benzoate (5ah): (SGS-6-76) Prepared following **General procedure B** using 3-cinnamoyloxazolidin-2-one (**4a**, 43.4 mg, 0.2 mmol, 1.0 equiv) and 4-allyl-2-methoxyphenyl 4-(*N,N*-dipropylsulfamoyl)benzoate (**1h**, 258.9 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 3:1) to afford the title compound as a yellow foam with diastereomers eluting separately as yellow foams with a 1.5:1 d.r. and 89% total yield. (major diastereomers 69.5 mg 53%) (minor diastereomers 46.4 mg, 36%).

Major Isomer

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 8.3 Hz, 2H), 7.93 (d, *J* = 8.3 Hz, 2H), 7.30 (t, *J* = 7.4 Hz, 1H), 7.25 (d, *J* = 6.8 Hz, 1H), 7.21 (t, *J* = 7.1 Hz, 1H), 7.09 (d, *J* = 8.0 Hz, 1H), 6.94 – 6.86 (m, 2H), 5.85 – 5.71 (m, 1H), 4.85 (d, *J* = 10.2 Hz, 1H), 4.76 (d, *J* = 17.0 Hz, 1H), 4.29 (q, *J* = 8.5 Hz, 1H), 4.19 (q, *J* = 8.6 Hz, 1H), 3.82 (s, 3H), 3.78 – 3.66 (m, 3H), 3.63 – 3.56 (m, 1H), 3.33 (dd, *J* = 16.6, 6.0 Hz, 1H), 3.24 (dd, *J* = 16.6, 7.8 Hz, 1H), 3.15 – 3.09 (m, 4H), 1.61 – 1.53 (m, 4H), 0.89 (t, *J* = 7.4 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 171.9, 163.6, 153.5, 151.0, 144.8, 142.4, 141.6, 139.5, 138.4, 132.8, 131.0, 128.6, 128.4, 127.2, 126.8, 122.6, 120.9, 116.4, 112.9, 62.0, 56.1, 56.0, 50.1, 46.8, 42.5, 39.7, 22.1, 11.3.

HRMS (ESI) calcd for C₃₅H₄₁N₂O₈S [M+H]⁺: 649.25781, found: 649.25814


Minor Isomer

¹H NMR (500 MHz, CDCl₃) δ 8.26 (d, *J* = 8.4 Hz, 2H), 7.90 (d, *J* = 8.5 Hz, 2H), 7.15 (t, *J* = 7.4 Hz, 2H), 7.12 – 7.02 (m, 3H), 6.92 (d, *J* = 8.1 Hz, 1H), 6.69 (dd, *J* = 8.2, 1.8 Hz, 1H), 6.55 (d, *J* = 1.7 Hz, 1H), 6.11 (dt, *J* = 17.0, 9.8 Hz, 1H), 5.23 (d, *J* = 16.9 Hz, 1H), 5.16 (dd, *J* = 10.1, 1.3 Hz, 1H), 4.32 (td, *J* = 9.0, 6.7

Hz, 1H), 4.24 (td, $J = 9.0, 7.3$ Hz, 1H), 3.90 – 3.77 (m, 2H), 3.68 – 3.60 (m, 4H), 3.59 – 3.40 (m, 3H), 3.15 – 3.05 (m, 4H), 1.56 (dq, $J = 14.9, 7.4$ Hz, 4H), 0.88 (t, $J = 7.4$ Hz, 6H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.3, 163.5, 153.6, 150.6, 144.8, 141.9, 141.8, 139.6, 137.9, 132.9, 130.95, 128.5, 128.2, 127.2, 126.6, 122.3, 120.2, 117.1, 112.7, 62.1, 57.1, 56.0, 50.1, 46.7, 42.6, 39.4, 22.1, 11.3.

HRMS (ESI) calcd for $\text{C}_{35}\text{H}_{41}\text{N}_2\text{O}_8\text{S}$ $[\text{M}+\text{H}]^+$: 649.25781, found: 649.25785.



3-(3-(4-Chlorophenyl)-4-(perfluorophenyl)hex-5-enoyl)oxazolidin-2-one (5bj): (SGS-7-8)

Prepared following **General procedure B** using 3-(3-(4-chlorophenyl)acryloyl)oxazolidin-2-one (**4b**, 43.4 mg, 0.2 mmol, 1.0 equiv) and allylpentafluorobenzene (**1j**, 91 μL , 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 $^\circ\text{C}$ for 24 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 3:1) to afford the title compound as a brown foam (58.2 mg, 63%, 1.4:1 d.r.).


^1H NMR (500 MHz, CDCl_3) δ 7.31 – 7.27 (m, 2H *), 7.21 – 7.09 (m, 2H * +4H $'$), 6.10 (dt, $J = 17.1, 9.7$ Hz, 1H $'$), 5.90 – 5.78 (m, 1H *), 5.30 (d, $J = 16.8$ Hz, 1H $'$), 5.19 (d, $J = 9.9$ Hz, 1H $'$), 4.85 (d, $J = 10.1$ Hz, 2H *), 4.77 (d, $J = 16.9$ Hz, 2H *), 4.38 – 4.21 (m, 2H * +2H $'$), 4.03 – 3.94 (m, 1H * +1H $'$), 3.93 – 3.72 (m, 3H * +3H $'$), 3.54 – 3.48 (m, 1H * +1H $'$), 3.39 (dd, $J = 17.3, 3.9$ Hz, 1H $'$), 2.83 (dd, $J = 16.7, 3.8$ Hz, 1H *).

^{13}C NMR (126 MHz, CDCl_3) δ 171.3, 170.8, 153.6, 153.4, 139.9, 139.6, 135.8, 135.1, 133.1, 133.0, 130.0, 129.7, 129.1, 129.0, 128.9, 128.8, 120.2, 118.9, 62.2, 62.1, 46.7, 45.9, 43.8, 42.9, 42.6, 42.5, 40.3, 39.6. Peaks missing from complex C-F coupling and overlap.

^{19}F NMR (376 MHz, CDCl_3) δ -140.68, -141.75, -155.56 (t, $J = 21.0$ Hz), -156.01 (t, $J = 21.1$ Hz), -161.24 (td, $J = 22.1, 8.0$ Hz), -161.92 (td, $J = 22.1, 7.7$ Hz).

HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{16}\text{NO}_3\text{ClF}_5$ $[\text{M}+\text{H}]^+$: 460.07334, found: 460.07292.

2.3 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Phthalimides



2-(1-Oxo-1,4-diphenylhex-5-en-3-yl)isoindoline-1,3-dione (7aa): (SGS-5-144) Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2


mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a tan foam (73.2 mg, 93%, 1.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.94 – 7.90 (m, 2H'), 7.86 – 7.10 (m, 14H* + 11H'), 7.06 – 7.00 (m, 1H'), 6.07 (dt, J = 16.9, 9.8 Hz, 1H'), 5.95 (dt, J = 16.9, 9.9 Hz, 1H*), 5.35 (d, J = 16.8 Hz, 1H'), 5.26 – 5.15 (m, 1H* + 2H'), 5.02 (dd, J = 16.8, 0.9 Hz, 1H*), 4.86 (dd, J = 10.0, 1.4 Hz, 1H*), 4.27 – 4.04 (m, 2H* + 2H'), 3.59 (dd, J = 17.8, 3.3 Hz, 1H'), 2.93 (dd, J = 17.7, 2.8 Hz, 1H*). Throughout analysis of diastereomeric mixtures, H* indicates the major diastereomer, while H' indicates the minor diastereomer.

¹³C NMR (101 MHz, CDCl₃) δ 197.6, 197.5, 168.6, 168.2, 140.9, 140.4, 139.0, 138.6, 136.7, 136.5, 134.0, 133.7, 133.4, 133.3, 131.8, 131.5, 129.4, 128.7, 128.6, 128.2, 128.1₂, 128.0₅, 127.8, 127.5, 127.1, 123.3, 123.1, 118.1, 117.2, 53.5₀, 53.4₅, 51.2, 50.2, 39.0, 38.1 (one carbon missing due to overlap). Note: ¹³C signals for the phthalimide carbonyl peaks are extremely broad for this and similar examples and many scans are required to adequate S/N for these peaks.

HRMS (ESI) calcd for C₂₆H₂₂O₃N [M+H]⁺: 396.16116, found: 396.15942.

1 mmol scale reaction: A 25 mL round bottom flask equipped with a magnetic stir bar and septa was flame dried under vacuum and transferred into an argon-filled glovebox. In the glovebox were sequentially added [Cp*Fe(CO)₂(thf)]⁺[BF₄]⁻ (20 mol %, 82.2 mg), LiNTf₂ (170.0 mg, 0.6 equiv), 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 277.5 mg, 1.0 mmol, 1.0 equiv), and dry DCE (0.65 mL, 1.5 M). The solution was briefly stirred. Then allylbenzene (**1a**, 395 μ L, 3.0 equiv), TIPSOTf (670 μ L, 1.5 equiv), and collidine (375 μ L, 3.0 equiv) were sequentially added with brief stirring after each addition. The flask was then sealed and removed from the glovebox and placed in an oil bath at 80 °C for 16 h at 400 rpm. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a silica plug using ethyl acetate. The crude mixture was concentrated *in vacuo*. The crude mixture was purified by flash column chromatography (hexanes/ethyl acetate = 20:1) to afford the title compound as a brown oil (350.4 mg, 89% yield, 1.2:1 d.r.).




2-(4-(Benzo[d][1,3]dioxol-5-yl)-1-oxo-1-phenylhex-5-en-3-yl)isoindoline-1,3-dione (7ae): (SGS-6-1) Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and safrole (**1e**, 89 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a white foam (62.3 mg, 71%, 1.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.93 – 7.89 (m, 2H'), 7.85 – 7.74 (m, 4H*), 7.70 – 7.63 (m, 2H*+2H'), 7.60 – 7.55 (m, 2H'), 7.55 – 7.50 (m, 1H), 7.50 – 7.45 (m, 1H), 7.44 – 7.39 (m, 2H), 7.39 – 7.34 (m, 2H), 6.89 (d, J = 1.6 Hz, 1H*), 6.86 (dd, J = 8.0, 1.7 Hz, 1H*), 6.80 (d, J = 7.9 Hz, 1H*), 6.74 (d, J = 1.7 Hz, 1H'), 6.65 (dd, J = 8.0, 1.7 Hz, 1H'), 6.57 (d, J = 8.0 Hz, 1H'), 6.00 (dt, J = 16.9, 9.8 Hz, 1H*), 5.96 – 5.85

(m, 2H*+ 1H'), 5.80 (dd, $J = 12.4, 1.5$ Hz, 2H'), 5.33 (d, $J = 16.7$ Hz, 1H'), 5.20 – 5.09 (m, 1H*+ 2H'), 5.00 (dd, $J = 16.8, 0.8$ Hz, 1H*), 4.85 (dd, $J = 10.0, 1.4$ Hz, 1H*), 4.17 – 4.01 (m, 2H*+2H'), 3.56 (dd, $J = 17.8, 3.3$ Hz, 1H'), 3.00 (dd, $J = 17.8, 2.9$ Hz, 1H*).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 197.6, 197.5, 148.4, 147.7, 146.9, 146.5, 139.1, 138.6, 136.8, 136.6, 134.7, 134.3, 134.0, 133.8, 133.4, 133.3, 131.8, 131.6, 128.7₄, 128.6₅, 128.2₁, 128.1₅, 123.2, 121.3, 120.9, 117.9, 117.1, 109.0, 108.4, 108.2, 108.1, 101.3, 101.0, 53.0₇, 53.0₅, 51.3, 50.4, 39.0, 38.1. One peak missing due to overlap. Phthalimide carbonyls not observed.

HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{22}\text{NO}_5$ $[\text{M}+\text{H}]^+$: 440.14925, found: 440.14857.




2-(4-(2-Bromophenyl)-1-oxo-1-phenylhex-5-en-3-yl)isoindoline-1,3-dione (7ag): (SGS-6-2)

Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and 2-bromoallylbenzene (**1g**, 89 μL , 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a white foam (75.5 mg, 81%, 1.6:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.93 (d, $J = 7.5$ Hz, 2H'), 7.88 – 7.71 (m, 3H*+1H'), 7.71 – 7.51 (m, 4H*+4H'), 7.51 – 7.32 (m, 5H*+4H'), 7.23 (t, $J = 7.5$ Hz, 1H'), 7.10 (t, $J = 7.3$ Hz, 1H*), 6.93 (t, $J = 7.3$ Hz, 1H'), 5.96 – 5.82 (m, 2H*+2H'), 5.46 (d, $J = 16.9$ Hz, 1H'), 5.37 (td, $J = 11.3, 3.5$ Hz, 1H'), 5.31 – 5.20 (m, 1H*), 5.18 (d, $J = 10.0$ Hz, 1H'), 5.13 (d, $J = 16.8$ Hz, 1H*), 4.96 – 4.83 (m, 2H*+1H'), 4.30 (dd, $J = 17.9, 10.9$ Hz, 1H*), 4.13 (dd, $J = 17.9, 9.7$ Hz, 1H'), 3.65 (dd, $J = 17.9, 3.6$ Hz, 1H'), 2.90 (dd, $J = 17.9, 2.7$ Hz, 1H*).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 197.5, 197.3, 168.8, 168.0, 140.0, 139.2, 138.0, 137.2, 136.7, 136.5, 134.0, 133.8, 133.6, 133.4, 133.4, 133.2, 131.6, 129.0, 128.7, 128.6, 128.4, 128.3, 128.2, 128.1, 127.8, 125.3, 124.8, 123.7, 123.2, 123.1, 118.8, 118.5, 51.8, 51.3, 50.7, 49.3, 39.2, 37.5. Missing two due to overlap.

HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{21}\text{NO}_3\text{Br}$ $[\text{M}+\text{H}]^+$: 474.06993, found: 474.07021.




2-(4-Benzyl-1-oxo-1-phenylhex-5-en-3-yl)isoindoline-1,3-dione (7ak): (SGS-6-3) Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5

mg, 0.2 mmol, 1.0 equiv) and 4-phenyl-1-butene (**1k**, 90 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a white foam (53.8 mg, 66%, 1.0:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.94 – 7.85 (m, 2H*+2H'), 7.79 – 7.72 (m, 2H*+2H'), 7.68 – 7.63 (m, 2H*+2H'), 7.56 – 7.49 (m, 1H*+1H'), 7.44 – 7.39 (m, 2H*+2H'), 7.29 – 7.23 (m, 1H*+1H'), 7.17 (t, J = 7.4 Hz, 1H*+2H'), 7.10 (t, J = 7.5 Hz, 1H*+1H'), 7.03 (d, J = 7.2 Hz, 1H*+1H'), 6.98 (t, J = 7.3 Hz, 1H*), 5.68 – 5.51 (m, 1H*+1H'), 5.10 – 5.00 (m, 1H*+1H'), 4.97 (td, J = 9.7, 3.8 Hz, 1H'), 4.88 (td, J = 10.5, 3.4 Hz, 1H*), 4.75 (ddd, J = 18.3, 13.6, 1.5 Hz, 1H*+1H'), 4.19 (dd, J = 17.8, 9.8 Hz, 1H*), 4.03 (dd, J = 17.9, 10.3 Hz, 1H'), 3.53 – 3.49 (m, 1H*), 3.49 – 3.44 (m, 1H'), 3.30 (qd, J = 9.6, 5.3 Hz, 1H'), 3.16 (qd, J = 9.9, 4.1 Hz, 1H*), 3.01 (dd, J = 13.7, 4.1 Hz, 1H'), 2.76 (dd, J = 13.9, 5.2 Hz, 1H*), 2.65 – 2.53 (m, 1H*+1H').

¹³C NMR (126 MHz, CDCl₃) δ 197.7, 197.4, 168.5₈, 168.5₇, 139.4, 139.3, 138.7, 137.9, 136.6, 136.7, 133.9, 133.4, 133.3, 131.8, 131.8, 129.3, 129.1, 128.7, 128.7, 128.3, 128.2, 128.1₄, 128.1₀, 126.6, 125.8, 123.3, 119.0, 118.3, 50.6, 50.4, 49.4, 48.3, 39.1, 38.8, 38.7, 38.6.

HRMS (ESI) calcd for C₂₇H₂₄NO₃ [M+H]⁺: 410.17507, found: 410.17352.



2-(1-Oxo-4-(perfluorophenyl)-1-phenylhex-5-en-3-yl)isoindoline-1,3-dione (7aj): (SGS-6-4)


Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and allylpentafluorobenzene (**1j**, 91 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a white foam (72.1 mg, 74%, 1.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.92 – 7.89 (m, 2H'), 7.87 – 7.75 (m, 3H*+1H'), 7.75 – 7.68 (m, 3H*+1H'), 7.67 – 7.62 (m, 2H'), 7.57 – 7.49 (m, 1H*+1H'), 7.45 – 7.36 (m, 2H*+2H'), 6.25 – 6.15 (m, 1H'), 6.15 – 6.04 (m, 1H*), 5.51 – 5.40 (m, 1H*+2H'), 5.32 (d, J = 9.9 Hz, 1H'), 5.16 (d, J = 16.8 Hz, 1H*), 5.02 (d, J = 10.0 Hz, 1H*), 4.64 (t, J = 10.5 Hz, 1H*+1H'), 4.14 (dd, J = 17.6, 9.8 Hz, 1H*+1H'), 3.57 (dd, J = 18.0, 3.8 Hz, 1H'), 3.04 (dd, J = 17.6, 4.0 Hz, 1H*).

¹³C NMR (101 MHz, CDCl₃) δ 196.8, 196.3, 168.8, 167.9, 146.7 – 146.2 (m), 144.2 – 143.8 (m), 142.1 – 141.3 (m), 139.7 – 138.4 (m), 136.9 – 136.6 (m), 136.5, 136.3, 136.2 – 135.8 (m), 134.2₃, 134.2₁, 133.9, 133.6, 133.6, 131.6, 131.3, 128.7₉, 128.7₇, 128.2, 128.1, 123.7, 121.4, 120.5, 114.9 – 113.2 (m), 48.6, 48.5, 43.8, 43.2, 38.8, 38.4. Carbon spectra was run an extended time to attempt to resolve low intensity peaks, however, some carbons are still missing due to complex C-F coupling and overlap.

¹⁹F NMR (471 MHz, CDCl₃) δ -140.61, -154.70 (t, J = 20.9 Hz), -155.09 (t, J = 21.0 Hz), -160.77 (td, J = 21.9, 7.9 Hz), -161.33 (td, J = 22.0, 7.8 Hz). One peak missing due to overlap.

HRMS (ESI) calcd for $C_{26}H_{17}NO_3F_5$ $[M+H]^+$: 486.11231, found: 486.11205.




2-(4-(4-Methoxyphenyl)-1-oxo-1-phenylhex-5-en-3-yl)isoindoline-1,3-dione (7ac): (SGS-6-5)

Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and allylanisole (**1c**, 92 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a clear oil (75.2 mg, 88%, 1.5:1 d.r.).

¹H NMR (500 MHz, $CDCl_3$) δ 7.94 – 7.90 (m, 2H[']), 7.80 (s (br), 1H^{*}+1H[']), 7.77 – 7.73 (m, 2H^{*}), 7.70 – 7.60 (m, 2H^{*}+2H[']), 7.58 – 7.49 (m, 2H^{*}+1H[']), 7.47 (t, J = 7.4 Hz, 1H^{*}), 7.42 (t, J = 7.7 Hz, 2H[']), 7.38 – 7.29 (m, 2H^{*}+2H[']), 7.16 – 7.11 (m, 2H[']), 6.94 – 6.88 (m, 2H^{*}), 6.71 – 6.66 (m, 2H[']), 6.04 (dt, J = 17.0, 9.8 Hz, 1H[']), 5.93 (dt, J = 16.9, 9.8 Hz, 1H^{*}), 5.32 (d, J = 16.9 Hz, 1H[']), 5.22 – 5.14 (m, 1H^{*}+2H[']), 5.00 (dd, J = 16.8, 0.9 Hz, 1H^{*}), 4.84 (dd, J = 10.0, 1.4 Hz, 1H^{*}), 4.21 – 4.05 (m, 2H^{*}+2H[']), 3.79 (s, 3H^{*}), 3.65 (s, 3H[']), 3.59 (dd, J = 17.7, 3.2 Hz, 1H[']), 2.98 (dd, J = 17.7, 2.8 Hz, 1H^{*}).

¹³C NMR (126 MHz, $CDCl_3$) δ 197.7, 197.5, 158.9, 158.5, 139.4, 138.9, 136.8, 136.6, 133.9, 133.7, 133.4, 133.3, 132.9, 132.5, 131.9, 131.5, 129.0, 128.7, 128.6, 128.2, 128.1, 123.1, 117.6, 116.8, 114.8, 114.1, 55.4, 55.2, 52.6, 52.6, 51.4, 50.4, 39.1, 38.1. One peak missing due to overlap. Phthalimide carbonyls not observed.

HRMS (ESI) calcd for $C_{27}H_{24}NO_4$ $[M+H]^+$: 426.16961, found: 426.16998.




2-(1-Oxo-1-phenyl-4-(o-tolyl)hex-5-en-3-yl)isoindoline-1,3-dione (7ai): (SGS-6-6) Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and 2-methylallylbenzene (**1i**, 88 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a clear oil (68.2 mg, 83%, 1.8:1 d.r.).

¹H NMR (500 MHz, $CDCl_3$) δ 7.93 (d, J = 7.5 Hz, 2H[']), 7.90 – 7.71 (m, 3H^{*}+2H[']), 7.70 – 7.65 (m, 2H^{*}), 7.65 – 7.61 (m, 2H[']), 7.57 – 7.50 (m, 1H^{*}+1H[']), 7.50 – 7.39 (m, 2H^{*}+2H[']), 7.38 – 7.31 (m, 2H^{*}+1H[']), 7.26 – 7.18 (m, 2H^{*}), 7.15 (t, J = 7.3 Hz, 1H^{*}), 7.09 (t, J = 7.2 Hz, 1H[']), 6.99 – 6.91 (m, 2H[']), 5.95 – 5.83 (m, 1H^{*}+1H[']), 5.38 – 5.24 (m, 1H^{*}+2H[']), 5.13 (d, J = 10.0 Hz, 1H[']), 5.00 (d, J = 16.9 Hz, 1H^{*}), 4.85 (d,

$J = 10.0$ Hz, $1H^*$), 4.58 (t, $J = 10.4$ Hz, $1H'$), $4.53 - 4.45$ (t, $J = 10.4$ Hz, $1H^*$), $4.17 - 4.02$ (m, $1H^*+1H'$), 3.65 (dd, $J = 17.6, 3.2$ Hz, $1H'$), 2.92 (dd, $J = 17.5, 2.5$ Hz, $1H^*$), 2.51 (s, $3H^*$), 2.33 (s, $3H'$).

^{13}C NMR (126 MHz, $CDCl_3$) δ 197.6, 197.4, 169.0, 168.0, 139.3, 138.7, 138.4, 138.0, 136.7, 136.4, 136.4, 136.2, 133.9, 133.7, 133.3, 133.2, 131.0, 130.6, 128.6, 128.5, 128.1, 128.0, 127.0, 126.9, 126.8, 126.5, 126.4, 126.2, 123.6, 123.0, 117.4, 117.0, 51.3, 49.3, 48.8, 47.6, 39.2, 37.4, 20.1, 19.4.

HRMS (ESI) calcd for $C_{27}H_{24}NO_3$ $[M+H]^+$: 410.17507, found: 410.17531.




4-(1,3-Dioxoisindolin-2-yl)-6-oxo-6-phenyl-3-vinylhexyl 5-bromofuran-2-carboxylate (7an):

(SGS-6-7) Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and pent-4-en-1-yl 5-bromofuran-2-carboxylate (**1n**, 155.0 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a clear oil (44.0 mg, 41%, 1.1:1 d.r.).

1H NMR (500 MHz, $CDCl_3$) δ 7.94 – 7.90 (m, $2H'$), 7.89 – 7.85 (m, $2H^*$), 7.83 – 7.79 (m, $2H^*$), 7.79 – 7.75 (m, $2H'$), 7.72 – 7.68 (m, $2H^*$), 7.68 – 7.63 (m, $2H'$), 7.52 (dd, $J = 15.7, 7.5$ Hz, $1H^*+1H'$), 7.41 (dd, $J = 16.4, 8.2$ Hz, $2H^*+2H'$), 7.13 (d, $J = 3.5$ Hz, $1H'$), 7.08 (d, $J = 3.5$ Hz, $1H^*$), 6.46 (d, $J = 3.5$ Hz, $1H'$), 6.43 (d, $J = 3.5$ Hz, $1H^*$), 5.68 – 5.55 (m, $1H^*+1H'$), 5.35 – 5.24 (m, $2H^*$), 5.07 – 4.98 (m, $2H'$), 4.90 (td, $J = 9.6, 3.9$ Hz, $1H'$), 4.80 (td, $J = 10.5, 3.5$ Hz, $1H^*$), 4.39 – 4.33 (m, $1H'$), 4.32 – 4.23 (m, $1H^*+1H'$), 4.20 – 4.13 (m, $1H^*+1H'$), 4.02 (dd, $J = 18.0, 10.2$ Hz, $1H^*$), 3.50 – 3.38 (m, $1H^*+1H'$), 3.07 (qd, $J = 10.9, 2.9$ Hz, $1H^*$), 2.98 (qd, $J = 10.2, 3.2$ Hz, $1H'$), 2.14 – 2.05 (m, $1H'$), 1.89 – 1.79 (m, $1H^*$), 1.79 – 1.70 (m, $1H'$), 1.69 – 1.60 (m, $1H^*$).

^{13}C NMR (126 MHz, $CDCl_3$) δ 197.6, 197.3, 168.6, 168.5, 157.6, 157.5, 146.4, 138.0, 137.3, 136.7, 136.6, 134.2, 134.0, 133.5, 133.4, 131.8, 131.6, 128.8, 128.7, 128.2₁, 128.1₇, 127.8, 127.7, 123.5, 123.4, 120.3, 120.2, 120.1, 119.1, 114.1, 114.0, 63.3, 62.9, 50.3, 50.0, 44.8, 44.1, 38.9, 38.3, 30.7, 30.0. One peak missing due to overlap.

HRMS (ESI) calcd for $C_{27}H_{23}NO_6Br$ $[M+H]^+$: 536.07033, found: 536.07027.




2,2'-(6-Oxo-6-phenylhex-1-ene-3,4-diyl)bis(isoindoline-1,3-dione) (7ap): (SGS-6-8) Prepared following **General procedure C** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5

mg, 0.2 mmol, 1.0 equiv), 2-allylisoindoline-1,3-dione (**1p**, 124.7 mg, 0.6 mmol, 3.0 equiv), and LiNTf₂ (46.0 mg, 0.16 mmol, 0.8 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (69.4 mg, 75%, 1.1:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.92 – 7.87 (m, 2H'), 7.86 – 7.77 (m, 2H*+1H'), 7.75 – 7.65 (m, 4H*+4H'), 7.66 – 7.61 (m, 2H), 7.61 – 7.57 (m, 2H), 7.53 (t, J = 7.4 Hz, 1H'), 7.47 (t, J = 7.4 Hz, 1H*), 7.42 (t, J = 7.7 Hz, 2H'), 7.35 (t, J = 7.8 Hz, 2H*), 6.58 (dt, J = 17.1, 9.9 Hz, 1H'), 6.42 (dt, J = 17.1, 9.8 Hz, 1H*), 5.73 (td, J = 9.8, 4.1 Hz, 1H'), 5.66 – 5.55 (m, 1H*+1H'), 5.49 – 5.37 (m, 1H*+2H'), 5.30 (d, J = 17.1 Hz, 1H*), 5.14 (d, J = 10.2 Hz, 1H*), 4.25 – 4.13 (m, 1H*+1H'), 3.49 (dd, J = 18.1, 3.9 Hz, 1H*), 3.34 (dd, J = 17.8, 4.1 Hz, 1H').

¹³C NMR (126 MHz, CDCl₃) δ 196.7, 196.5, 168.3, 168.0, 167.8, 136.7, 136.5, 134.4, 134.2, 134.1, 133.6, 133.5, 132.5, 132.1, 131.9₃, 131.9₀, 131.8, 131.7, 128.9, 128.8, 128.3₀, 128.2₉, 123.7, 123.6, 123.6, 122.6, 121.6, 56.5, 55.9, 48.1₀, 48.0₅, 37.9, 37.5. Three peaks missing due to overlap.

HRMS (ESI) calcd for C₂₈H₂₁N₂O₅ [M+H]⁺: 465.14450, found: 465.14344.




9-(1,3-Dioxoisindolin-2-yl)-11-oxo-11-phenyl-8-vinylundecyl 4-methylbenzenesulfonate (7am): (SGS-6-18) Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and dec-9-en-1-yl 4-methylbenzenesulfonate (**1m**, 279.4 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a brown oil (91.8 mg, 78%, 1.1:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.85 – 7.80 (m, 2H*), 7.80 – 7.76 (m, 2H'), 7.74 – 7.63 (m, 4H*+4H'), 7.61 – 7.57 (m, 2H'), 7.57 – 7.53 (m, 2H*), 7.46 – 7.38 (m, 1H*+1H'), 7.35 – 7.28 (m, 2H*+2H'), 7.26 – 7.21 (m, 2H*+2H'), 5.43 (ddt, J = 27.1, 17.0, 10.0 Hz, 1H*+1H'), 5.17 – 5.06 (m, 2H'), 4.87 – 4.76 (m, 2H*), 4.70 (td, J = 9.9, 3.8 Hz, 1H*), 4.62 (td, J = 10.5, 3.4 Hz, 1H'), 4.01 (dd, J = 17.8, 9.9 Hz, 1H*), 3.95 – 3.80 (m, 2H*+3H'), 3.35 (dd, J = 17.9, 3.4 Hz, 1H'), 3.29 (dd, J = 17.8, 3.8 Hz, 1H*), 2.80 – 2.63 (m, 1H*+1H'), 2.34 (s, 3H*), 2.34 (s, 3H'), 1.56 – 1.37 (m, 4H*+4H'), 1.28 – 0.93 (m, 10H*+10H').

¹³C NMR (126 MHz, CDCl₃) δ 198.0, 197.7, 168.6, 144.8, 144.7, 139.5, 138.9, 136.8, 134.1, 133.9, 133.4, 133.3, 131.9, 131.8, 129.9₄, 129.9₂, 128.8, 128.7, 128.2₁, 128.1₈, 128.0₂, 128.0₁, 123.4, 123.3, 118.8, 117.8, 70.8, 50.6, 50.3, 47.7, 47.0, 38.9, 38.5, 31.8, 30.9, 29.5, 29.2, 29.0, 28.9₂, 28.9₀, 28.9, 27.2, 26.7, 25.4, 25.3, 21.8. Four peaks missing due to overlap.

HRMS (ESI) calcd for C₃₄H₃₈NO₆S [M+H]⁺: 588.24144, found: 588.24084.




4-(1,3-Dioxoisindolin-2-yl)-6-oxo-6-phenyl-3-vinylhexyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (7aq): (SGS-6-17) Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and pent-4-en-1-yl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (**1q**, 273.9 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (71.4 mg, 60%, 1.1:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.85 – 7.81 (m, 2H'), 7.81 – 7.77 (m, 2H*), 7.71 – 7.65 (m, 2H*+2H'), 7.60 – 7.54 (m, 2H*+2H'), 7.47 – 7.40 (m, 1H*+1H'), 7.34 – 7.30 (m, 2H*+2H'), 6.90 (dd, *J* = 7.4, 3.2 Hz, 1H*+1H'), 6.60 – 6.55 (m, 1H*+1H'), 6.53 (d, *J* = 11.4 Hz, 1H*+1H'), 5.57 – 5.43 (m, 1H*+1H'), 5.26 – 5.15 (m, 2H*), 4.95 – 4.87 (m, 2H'), 4.79 (td, *J* = 9.7, 3.9 Hz, 1H'), 4.70 (td, *J* = 10.5, 3.5 Hz, 1H*), 4.11 – 3.75 (m, 5H*+5H'), 3.38 (dd, *J* = 18.0, 3.5 Hz, 1H*), 3.30 (dd, *J* = 17.8, 3.9 Hz, 1H'), 2.97 (qd, *J* = 11.1, 2.9 Hz, 1H*), 2.87 (qd, *J* = 10.4, 3.0 Hz, 1H'), 2.22 (s, 3H*), 2.21 (s, 3H'), 2.08 (s, 3H'), 2.05 (s, 3H*), 1.95 – 1.86 (m, 1H'), 1.71 – 1.39 (m, 6H*+5H'), 1.16 (s, 6H'), 1.09 (s, 6H*).

¹³C NMR (126 MHz, CDCl₃) δ 197.7, 197.3, 177.8, 177.7, 168.6, 168.5, 157.1, 138.1, 137.5, 136.7₁, 136.6₇, 136.5₅, 136.5₃, 134.1₀, 133.9₆, 133.5, 133.4, 131.8, 131.7, 130.4₀, 130.3₉, 128.8, 128.7, 128.1₇, 128.1₅, 123.7, 123.4, 123.3, 120.8₁, 120.7₇, 120.0, 118.9, 112.1₂, 112.0₉, 68.0, 62.4, 61.9, 50.3, 50.0, 44.8, 44.1, 42.2, 42.1, 38.9, 38.3, 37.2, 37.1, 30.6, 30.0, 25.4, 25.3₃, 25.2₉, 25.3, 25.2, 21.5, 15.8₉, 15.8₆. Five peaks missing due to overlap.

HRMS (ESI) calcd for C₃₇H₄₂NO₆ [M+H]⁺: 596.30066, found: 596.30116.



2-(1-(Cyclopent-2-en-1-yl)-3-oxo-3-phenylpropyl)isoindoline-1,3-dione (7al): (SGS-6-23)


Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and cyclopentene (**1l**, 53 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow oil (45.3 mg, 65%, 1.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, *J* = 7.6 Hz, 2H*+2H'), 7.82 – 7.76 (m, 2H*+2H'), 7.71 – 7.64 (m, 2H*+2H'), 7.52 (t, *J* = 7.2 Hz, 1H*+1H'), 7.42 (t, *J* = 7.5 Hz, 2H*+2H'), 5.96 – 5.49 (m, 2H*+2H'), 4.79 – 4.66 (m, 1H*+1H'), 4.30 – 4.16 (m, 1H*+1H'), 3.56 – 3.43 (m, 1H*+1H'), 3.37 – 3.27 (m,

1H*+1H'), 2.51 – 2.22 (m, 2H*+2H'), 2.21 – 2.11 (m, 1H'), 1.99 – 1.89 (m, 1H*), 1.75 – 1.62 (m, 1H*+1H').

¹³C NMR (126 MHz, CDCl₃) δ 197.8, 168.9, 168.7, 136.9, 134.2, 134.0, 133.3, 132.0, 130.8₉, 130.8₇, 128., 128.2, 123.4, 123.3, 51.8, 51.5, 48.9₃, 48.8₆, 38.7, 38.6, 32.4, 31.7, 27.9, 27.2. Eight peaks missing due to overlap.

HRMS (ESI) calcd for C₂₂H₂₀NO₃ [M+H]⁺: 346.14377, found: 346.14273.




2-(1-Oxo-1-phenyl-9-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-vinylnonan-3-yl)isoindoline-1,3-dione (7ao): (SGS-6-53) Prepared following **General procedure D** using 2-(3-oxo-3-phenylprop-1-en-1-yl)isoindoline-1,3-dione (**6a**, 55.5 mg, 0.2 mmol, 1.0 equiv) and 4,4,5,5-tetramethyl-2-(4-(oct-7-en-1-yloxy)phenyl)-1,3,2-dioxaborolane (**1o**, 198.2 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 80 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 5:1) to afford the title compound as a tan foam (75.9 mg, 62%, 1.1:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, *J* = 7.5 Hz, 2H'), 7.88 (d, *J* = 7.5 Hz, 2H*), 7.83 – 7.61 (m, 6H*+6H'), 7.56 – 7.47 (m, 1H*+1H'), 7.46 – 7.36 (m, 2H*+2H'), 6.87 (d, *J* = 8.3 Hz, 2H*), 6.82 (d, *J* = 8.4 Hz, 2H'), 5.64 – 5.47 (m, 1H*+1H'), 5.22 (dd, *J* = 20.2, 13.6 Hz, 2H'), 4.99 – 4.88 (m, 2H*), 4.73 (td, *J* = 10.4, 3.1 Hz, 1H'), 4.81 (td, *J* = 9.9, 3.5 Hz, 1H*), 4.73 (td, *J* = 10.4, 3.1 Hz, 1H'), 4.13 (dd, *J* = 17.7, 10.0 Hz, 1H*), 3.99 (m, 2H*+1H'), 3.88 (t, *J* = 6.4 Hz, 2H'), 3.49 – 3.37 (m, 1H*+1H'), 2.92 – 2.76 (m, 1H*+1H'), 1.83 – 1.16 (m, 20H*+20H').

¹³C NMR (126 MHz, CDCl₃) δ 197.9, 197.6, 168.6, 161.7₉, 161.7₇, 139.4, 138.8, 136.7₉, 136.7₆, 136.6, 136.5, 134.0, 133.9, 133.4, 133.3, 131.8₄, 131.7₇, 128.7₂, 128.6₆, 128.2, 128.1, 123.4, 123.2, 118.9, 117.8, 114.0, 113.9, 83.6, 67.6₉, 67.6₆, 50.6, 50.3, 47.6, 47.0, 38.9, 38.4, 31.7, 30.9, 29.2₃, 29.1₅, 27.1, 26.7, 26.1, 25.9, 25.0. Three peaks missing due to overlap.

HRMS (ESI) calcd for C₃₇H₄₃BNO₆ [M+H]⁺: 608.31779, found: 608.31985.

2.4 Synthesis of Michael adducts from Fe-catalyzed Michael addition – Sulfonamides




***N*-Methyl-2-nitro-*N*-(1-oxo-1,4-diphenylhex-5-en-3-yl)benzenesulfonamide (9aa):** (SGS-5-184)

Prepared following **General procedure E** using *N*-methyl-2-nitro-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (**8a**, 69.3 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 5:1) to afford the title compound as a tan foam (66.9 mg, 72%, 1.2:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 7.97 – 7.94 (m, 1H'), 7.84 – 7.80 (m, 1H*+1H'), 7.74 (d, J = 7.9 Hz, 1H*), 7.56 – 7.38 (m, 6H*+6H'), 7.29 – 7.23 (m, 3H*+3H'), 7.18 – 7.12 (m, 1H*+2H'), 7.10 – 7.05 (m, 2H*+1H'), 6.11 (dt, J = 16.9, 9.7 Hz, 1H'), 5.87 (dt, J = 16.9, 9.9 Hz, 1H*), 5.10 (d, J = 4.9 Hz, 1H*), 5.06 (d, J = 5.4 Hz, 1H'), 5.02 – 4.90 (m, 1H*+2H'), 4.87 (dd, J = 10.0, 1.2 Hz, 1H*), 3.65 – 3.57 (m, 2H'), 3.46 (dd, J = 17.4, 6.7 Hz, 1H*), 3.25 (dd, J = 17.4, 4.2 Hz, 1H*), 3.05 (s, 3H'), 3.03 – 2.90 (m, 4H*+1H'). Throughout analysis of diastereomeric mixtures, H* indicates the major diastereomer, while H' indicates the minor diastereomer.

¹³C NMR (126 MHz, CDCl₃) δ 196.8₃, 196.7₆, 147.9, 147.6, 140.8, 140.5, 138.6, 138.3, 136.6, 136.2, 133.9, 133.4, 133.3, 133.2₄, 133.1₆, 131.7, 131.5, 131.4, 131.3, 129.2, 128.7₃, 128.6₅, 128.5, 128.4, 128.1, 128.0, 127.7, 127.5, 126.9, 124.4, 123.7, 117.7, 117.0, 59.1, 57.7, 55.6, 54.9, 41.0, 39.4. Two peaks missing due to overlap.

HRMS (ESI) calcd for C₂₅H₂₅N₂O₅S [M+H]⁺: 465.14787, found: 465.14707.



***N*,4-Dimethyl-*N*-(1-oxo-1,4-diphenylhex-5-en-3-yl)benzenesulfonamide (9ca):** (SGS-6-20)


Prepared following **General procedure E** using *N*,4-dimethyl-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (**8c**, 63.1 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μ L, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by

flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a tan foam (48.3 mg, 56%, 1.2:1 d.r.).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.76 (d, $J = 7.9$ Hz, 2H'), 7.59 – 7.04 (m, 14H*+10H'), 6.98 (d, $J = 7.9$ Hz, 2H'), 6.24 – 6.07 (m, 1H*), 5.93 (dt, $J = 17.2, 9.8$ Hz, 1H'), 5.16 – 4.83 (m, 3H*+3H'), 3.69 – 3.52 (m, 1H*+1H'), 3.30 (dd, $J = 17.3, 6.3$ Hz, 1H'), 3.03 (dd, $J = 17.3, 5.1$ Hz, 1H'), 2.96 – 2.75 (m, 5H*), 2.68 (s, 3H'), 2.29 (s, 3H*), 2.24 (s, 3H').

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 197.1, 196.9, 142.9, 142.9, 141.4, 140.9, 139.1, 138.8, 137.6, 136.8, 136.7, 136.3, 133.2, 133.1, 129.5, 129.4, 129.1, 128.8, 128.6, 128.5, 128.4, 128.1, 128.0, 127.4, 127.3, 127.0, 117.4, 116.8, 59.3, 57.6, 56.1, 55.1, 40.0, 39.6, 31.5, 30.5, 21.5₁, 21.4₆. Two peaks missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{28}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$: 434.17844, found: 434.17736.




***N*-Methyl-4-nitro-*N*-(1-oxo-1,4-diphenylhex-5-en-3-yl)benzenesulfonamide (9ba)**: (SGS-5-168-8) Prepared following **General procedure E** using *N*-methyl-4-nitro-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (**8b**, 69.3 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL , 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a tan foam (62.2 mg, 67%, 1.1:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.02 – 7.98 (m, 2H*), 7.93 – 7.88 (m, 2H'), 7.75 – 7.71 (m, 2H*), 7.69 – 7.65 (m, 2H'), 7.51 – 7.14 (m, 10H*+10H'), 6.14 (dt, $J = 16.9, 9.8$ Hz, 1H*), 5.90 (dt, $J = 16.9, 9.9$ Hz, 1H'), 5.15 – 4.92 (m, 2H*+2H'), 4.92 – 4.82 (m, 1H*+1H'), 3.61 (t, $J = 10.0$ Hz, 1H'), 3.50 (t, $J = 9.9$ Hz, 1H*), 3.31 (dd, $J = 17.2, 5.3$ Hz, 1H'), 3.11 (dd, $J = 17.2, 6.8$ Hz, 1H'), 2.90 (s, 3H*), 2.82 – 2.77 (m, 2H*), 2.74 (s, 3H').

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 196.8, 196.7, 149.7, 149.6, 146.3, 145.7, 141.1, 140.7, 138.6, 138.1, 136.2, 135.7, 133.7, 129.4, 129.0, 128.8, 128.7, 128.4, 128.3, 128.3, 128.1, 128.0₁, 127.9₉, 127.7, 127.3, 124.0, 118.2, 117.4, 60.1, 58.9, 55.8, 55.3, 40.0, 39.1. Two peaks missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{25}\text{N}_2\text{O}_5\text{S}$ $[\text{M}+\text{H}]^+$: 465.14787, found: 465.14648.




2-Methoxy-4-((N-methyl-2-nitrophenyl)sulfonamido)-6-oxo-6-phenylhex-1-en-3-yl)phenyl benzoate (9af): (SGS-6-30) Prepared following **General procedure E** using *N*-methyl-2-nitro-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (**8a**, 69.3 mg, 0.2 mmol, 1.0 equiv) and 2-methoxy-4-(6-oxo-4,6-diphenylhex-1-en-3-yl)phenyl benzoate (**1f**, 160.9 mg, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a brown foam (96.4 mg, 78%, 1.6:1 d.r.).

¹H NMR (500 MHz, CDCl₃) δ 8.19 (t, *J* = 6.5 Hz, 2H*+2H'), 7.97 – 7.91 (m, 1H'), 7.83 (d, *J* = 7.6 Hz, 1H*+1H'), 7.77 – 7.71 (m, 1H*), 7.67 – 7.31 (m, 10H*+10H'), 7.06 (d, *J* = 8.0 Hz, 1H'), 6.97 – 6.83 (m, 2H*+2H'), 6.76 (d, *J* = 7.9 Hz, 1H*), 6.15 – 6.04 (m, 1H'), 5.95 – 5.84 (m, 1H*), 5.18 – 5.06 (m, 1H*+1H'), 5.04 – 4.89 (m, 2H*+2H'), 3.79 (s, 3H'), 3.78 (s, 3H*), 3.73 – 3.59 (m, 2H'), 3.49 (dd, *J* = 17.2, 6.2 Hz, 1H*), 3.33 – 3.23 (m, 1H*), 3.15 – 2.92 (m, 4H*+4H').

¹³C NMR (126 MHz, CDCl₃) δ 197.0, 196.9, 164.7, 151.8, 151.4, 148.0, 147.8, 139.8, 139.5, 139.3, 138.9, 138.3, 137.9, 136.5, 136.2, 133.8, 133.7, 133.6, 133.5, 133.4, 133.3₃, 133.2₆, 133.0, 131.7, 131.5, 131.1, 131.0, 130.4, 129.6, 129.5, 128.8, 128.7, 128.6₃, 128.6₀, 128.1₁, 128.1₀, 124.5, 123.7, 123.4, 122.9, 120.6, 119.6, 118.0, 117.2, 112.5, 59.2, 58.0, 56.2, 56.1, 55.4, 54.7, 40.9, 39.6.

HRMS (ESI) calcd for C₃₃H₃₁N₂O₈S [M+H]⁺: 615.17956, found: 615.17866.




***N*-(4-benzyl-1-oxo-1-phenylhex-5-en-3-yl)-*N*-methyl-2-nitrobenzenesulfonamide (9ak):** (SGS-6-19) Prepared following **General procedure E** using *N*-methyl-2-nitro-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (**8a**, 69.3 mg, 0.2 mmol, 1.0 equiv) and 4-phenyl-1-butene (**1k**, 90 μL, 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by

flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a yellow foam (37.7 mg, 40%, 1.1:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.10 (dd, $J = 7.6, 0.6$ Hz, 1H'), 8.09 – 8.04 (m, 1H*), 7.82 (d, $J = 7.6$ Hz, 2H*), 7.74 (d, $J = 7.5$ Hz, 2H'), 7.64 – 7.37 (m, 6H*+6H'), 7.25 – 7.11 (m, 3H*+3H'), 7.07 (d, $J = 7.4$ Hz, 2H*+2H'), 5.58 (dt, $J = 17.1, 9.9$ Hz, 1H*), 5.46 (dt, $J = 17.1, 9.8$ Hz, 1H'), 4.91 – 4.59 (m, 3H*+3H'), 3.40 (dd, $J = 17.3, 7.2$ Hz, 1H*), 3.31 (dd, $J = 17.1, 6.7$ Hz, 1H'), 3.16 – 3.09 (m, 3H'+1H*), 3.05 – 2.98 (m, 3H*+1H'), 2.95 (dd, $J = 17.1, 4.4$ Hz, 1H*), 2.80 – 2.48 (m, 2H*+2H'), 2.31 (dd, $J = 13.6, 10.9$ Hz, 1H').

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 196.8, 196.6, 147.9, 147.8, 139.8, 139.5, 137.8, 137.6, 136.6, 136.5, 133.7, 133.5, 133.4, 133.4, 133.3, 132.0, 131.8₁, 131.7₈, 131.7, 129.4, 129.3, 128.8, 128.7, 128.3, 128.1, 128.0, 126.2, 126.1, 124.0, 123.9, 119.2, 118.6, 57.1, 56.5, 51.4, 50.4, 40.4, 40.3, 38.5, 38.1, 31.5, 30.6. Two peaks missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{N}_2\text{O}_5\text{S}$ $[\text{M}+\text{H}]^+$: 479.16352, found: 479.16176.




***N*-(1-Oxo-1,4-diphenylhex-5-en-3-yl)-*N*-phenethyl-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide (9da)**: (SGS-6-63) Prepared following **General procedure E** using *N*-(3-oxo-3-phenylprop-1-en-1-yl)-*N*-phenethyl-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide (**8d**, 123.1 mg, 0.2 mmol, 1.0 equiv) and allylbenzene (**1a**, 79 μL , 0.6 mmol, 3.0 equiv). The reaction mixture was heated at 60 °C for 16 h. The crude reaction mixture was purified by flash column chromatography (hexanes/ethyl acetate = 10:1) to afford the title compound as a very sticky brown solid, which trapped ethyl acetate despite significant removal attempts. (104.5 mg, 70%, 1.1:1 d.r.). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.84 – 7.78 (t, $J = 7.4$ Hz, 2H*+2H'), 7.56 – 7.48 (m, 1H*+1H'), 7.45 – 7.37 (dd, $J = 16.7, 8.4$ Hz, 2H*+2H'), 7.35 – 7.14 (m, 12H*+12H'), 7.13 – 6.98 (m, 6H*+6H'), 6.69 (s, 1H*), 6.68 (s, 1H'), 6.19 – 6.07 (m, 1H'), 5.77 (dt, $J = 16.9, 9.9$ Hz, 1H*), 5.14 – 4.79 (m, 3H*+3H'), 3.81 – 3.60 (m, 1H*+1H'), 3.59 – 3.27 (m, 2H*+2H'), 3.21 – 2.56 (m, 4H*+4H'), 2.32 (s, 3H*), 2.28 (s, 3H'). $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 197.0, 196.6, 145.2₄, 145.2₁, 144.0₆ (q, $J = 38.5$ Hz), 144.0₄ (q, $J = 38.5$ Hz), 142.3₄, 142.3₂, 141.3, 140.6, 140.5, 139.8₃, 139.8₁, 139.6, 139.2, 139.0, 138.8, 138.6₃, 136.5₅, 136.2, 133.4, 133.3, 129.8, 129.0, 128.9, 128.9, 128.8₄, 128.8₁, 128.7₇, 128.7₆, 128.7, 128.5₇, 128.5₅, 128.5, 128.2, 128.1, 127.9, 127.5, 127.2, 126.8₂, 126.7₇, 125.9, 125.3₀, 125.2₇, 121.2 (q, $J = 269.1$ Hz), 117.6, 117.4, 106.3, 56.9, 55.6, 42.4, 41.3, 36.9, 36.4, 29.8, 21.4₁, 21.3₇. Six peaks missing due to overlap.

^{19}F NMR (471 MHz, CDCl_3) δ -62.40. One peak missing due to overlap.

HRMS (ESI) calcd for $\text{C}_{43}\text{H}_{39}\text{N}_3\text{O}_3\text{F}_3\text{S}$ $[\text{M}+\text{H}]^+$: 734.26587, found: 734.26482.


2.5 Synthesis of Michael acceptor substrates

2.5.1 Maleimide Michael Acceptors



Maleimides **2a**, **2b**, **2c**, **2d**, **2f**, **2i**, and **2k** are commercial and were used directly without further purification.

Maleimides **2e**,² **2h**,³ **2j**,⁴ and **2l**⁵ were synthesized according to a known literature procedure and have been previously characterized.



1-(1-(2,6-Dimethylphenoxy)propan-2-yl)-1H-pyrrole-2,5-dione (**2g**): (SGS-5-191)

Mexiletine hydrochloride (647 mg, 3.0 mmol, 1.0 equiv) (note that the hydrochloride salt was simply chosen for the commercial availability of the compound and had no additional bearing on the reaction) and maleic anhydride (588.4 mg, 6.0 mmol, 2.0 equiv) were suspended in glacial acetic acid (4.5 mL). The reaction was refluxed with stirring at 125 °C for 48 hours. The reaction mixture was then cooled to room temperature and transferred to a 500 mL beaker. Saturated aqueous sodium bicarbonate was added until no additional gas evolution was observed. Ethyl acetate was added and the mixture was extracted with ethyl acetate. The combined organic fractions were washed with a 1N HCl solution, followed by a brine solution, and were then dried with magnesium sulfate, filtered, and concentrated. The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes = 3:1), affording **2g** (165.7 mg, 21% yield) as off white solid.

¹H NMR (500 MHz, CDCl₃) δ 6.97 (d, *J* = 7.5 Hz, 2H), 6.89 (dd, *J* = 8.0, 6.9 Hz, 1H), 6.70 (s, 2H), 4.71 – 4.62 (m, 1H), 4.23 (t, *J* = 9.3 Hz, 1H), 3.80 (dd, *J* = 9.4, 5.5 Hz, 1H), 2.20 (s, 6H), 1.46 (d, *J* = 7.1 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 171.0, 155.3, 134.2, 130.8, 129.0, 124.1, 71.6, 47.2, 16.3, 15.2.

HRMS (ESI) calcd for C₁₅H₁₈O₃N [M+H]⁺: 260.12812, found: 260.12816.

m.p. = 64 – 65 °C

2.5.2 *N*-Acyl oxazolidinone Michael Acceptors

All Michael acceptor starting materials were synthesized with an E/Z of >20% by NMR.

N-Acyl oxazolidinone Michael Acceptors **4a** and **4b** were synthesized according to a known literature procedure and have been previously characterized.⁶

2.5.3 Phthalimide protected Michael Acceptors


All Michael acceptor starting materials were synthesized with an E/Z of >20% by NMR.

The Michael acceptor **6a** was synthesized according a literature procedure and has been previously characterized.⁷

2.5.4 Sulfonamide protected Michael Acceptors:


All Michael acceptor starting materials were synthesized with an E/Z of >20% by NMR.

General Procedure F: Synthesis of sulfonamide protected Michael acceptors from alkynesones



To a flame dried round bottom flask containing the sulfonamide (2.0 mmol, 1.0 equiv) and DMAP (2.0 mmol 1.0 equiv) was added acetonitrile [0.1 M]. Alkyne was dissolved in minimal acetonitrile and then added dropwise at 0 °C with rapid stirring. Minimal color change upon alkyne addition is preferable, with poor yields observed with significant darkening of the reaction mixture. The reaction was stirred for two hours, gradually warming to room temperature. The mixture was filtered through a celite plug, then concentrated to dryness and purified by column chromatography.

The sulfonamide protected Michael acceptors **8b** and **8c** were synthesized according to General Procedure F and have been previously characterized.⁸



***N*-methyl-2-nitro-*N*-(3-oxo-3-phenylprop-1-en-1-yl)benzenesulfonamide (8a):** (SGS-5-181)


Prepared following **General Procedure F:** The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes = 2:1), affording **8a** (0.3027 g, 70% yield) as off white solid.

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.20 (d, $J = 13.5$ Hz, 1H), 8.12 (dd, $J = 7.5, 1.7$ Hz, 1H), 7.93 – 7.89 (m, 2H), 7.82 – 7.73 (m, 3H), 7.56 (t, $J = 7.4$ Hz, 1H), 7.47 (t, $J = 7.6$ Hz, 2H), 6.28 (d, $J = 13.5$ Hz, 1H), 3.30 (s, 3H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 189.5, 143.1, 138.4, 135.1, 132.8, 132.6, 131.5, 131.3, 128.7, 128.3, 125.1, 104.6, 33.5.

HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{15}\text{O}_5\text{N}_2\text{S}$ $[\text{M}+\text{H}]^+$: 347.06962, found: 347.07065.

m.p. = 158 – 159 °C



***N*-(3-oxo-3-phenylprop-1-en-1-yl)-*N*-phenethyl-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfonamide (**8d**):** (SGS-5-183)

Step 1. *N*-phenethyl-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfonamide was synthesized according to a known literature procedure and has been previously characterized.⁹

Step 2. Prepared following **General Procedure F**: The crude product was purified by flash column chromatography on silica (ethyl acetate/hexanes = 5:1), affording **8d** (0.2745 g, 73% yield) as yellow foam.

$^1\text{H NMR}$ (500 MHz, CDCl_3) 8.23 (d, $J = 13.7$ Hz, 1H), 7.85 – 7.79 (m, 4H), 7.55 (t, $J = 7.4$ Hz, 1H), 7.52 – 7.43 (m, 4H), 7.33 (t, $J = 7.4$ Hz, 2H), 7.28 – 7.22 (m, 1H), 7.20 (d, $J = 7.1$ Hz, 2H), 7.14 (d, $J = 7.9$ Hz, 2H), 7.08 (d, $J = 8.1$ Hz, 2H), 6.72 (s, 1H), 6.21 (d, $J = 13.7$ Hz, 1H), 3.75 – 3.68 (m, 2H), 3.01 – 2.91 (m, 2H), 2.35 (s, 3H).


$^{13}\text{C NMR}$ (126 MHz, CDCl_3) 189.3, 145.5, 144.5 (q, $J = 38.9$ Hz), 143.6, 142.3, 140.2, 138.5, 137.5, 137.4, 132.7, 123.0, 129.1, 128.8, 128.7, 128.4, 128.2, 127.3, 125.9, 125.7, 121.1 (q, $J = 269.3$ Hz), 106.8, 103.7, 48.2, 33.9, 21.5.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ –62.55.


HRMS (ESI) calcd for $\text{C}_{34}\text{H}_{29}\text{O}_3\text{N}_3\text{F}_3\text{S}$ $[\text{M}+\text{H}]^+$: 616.18762, found: 616.18750.

m.p. = 86 – 91 °C

2.6 Synthesis of alkene substrates



The alkenes **1a-1c**, **1e**, **1g**, and **1j-1l** are commercial, and were used directly without purification. The alkenes **1f** and **1m-1q**,¹⁰ and **1d**¹¹ were synthesized according to a known literature procedure and have been previously characterized.



4-Allyl-2-methoxyphenyl 4-(N,N-dipropylsulfamoyl)benzoate (**1h**) (SGS-6-62)

DCC (928 mg, 4.5 mmol, 1.5 equiv) was added to the solution of probenecid (856 mg, 3.0 mmol, 1.0 equiv) and eugenol (0.558 ml, 3.6 mmol, 1.2 equiv) in 15 mL of CH_2Cl_2 . The reaction mixture was stirred at room temperature overnight. The crude mixture filtered through celite and purified by flash chromatography (hexanes/ethyl acetate = 5:1) to obtain the pure compound as a white solid (342.8 mg, 26% yield).

¹H NMR (400 MHz, CDCl_3) δ 8.32 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 8.5 Hz, 2H), 7.07 (d, J = 7.9 Hz, 1H), 6.88 – 6.79 (m, 2H), 5.99 (ddt, J = 16.8, 10.1, 6.7 Hz, 1H), 5.20 – 5.07 (m, 2H), 3.81 (s, 3H), 3.42 (d, J = 6.7 Hz, 2H), 3.16 – 3.07 (m, 4H), 1.67 – 1.48 (m, 4H), 0.89 (t, J = 7.4 Hz, 6H).


¹³C NMR (101 MHz, CDCl_3) δ 163.7, 151.0, 144.8, 139.6, 138.0, 137.1, 133.0, 131.0, 127.3, 122.6, 120.9, 116.4, 113.0, 56.0, 50.2, 40.3, 22.1, 11.3.

HRMS (ESI) calcd for $C_{23}H_{30}O_5NS$ $[M+H]^+$: 432.18392, found: 432.18363.

m.p. = 105 – 106 °C

3. Synthetic applications of products

Synthesis of 3-(1-(4-Methoxyphenyl)allyl)-1-phenyl-1H-pyrrole (10) (SGS-6-94)




The following reaction was based on a literature procedure.¹² A reaction tube equipped with a magnetic stir bar was capped with a septum and flame dried under vacuum. **3fc** (32.3 mg, 0.1 mmol, 1.0 equiv), is dissolved in anhydrous THF (2.5 mL). $LiAlH_4$ (10.7 mg, 0.3 mmol, 3 equiv) was added in one portion under nitrogen stream. The flask sealed and stirred at room temperature for 16 h. The reaction is quenched with water at 0 °C. The crude reaction mixture is extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated. The crude reaction mixture was immediately purified by flash chromatography (hexanes/ethyl acetate = 5:1) to give the pure product **10** as a yellow oil (24.6 mg, 85% yield).

¹H NMR (500 MHz, $CDCl_3$) δ 7.42 – 7.33 (m, 4H), 7.25 – 7.18 (m, 3H), 7.05 (t, J = 2.6 Hz, 1H), 6.90 – 6.85 (m, 2H), 6.81 (s, 1H), 6.26 (ddd, J = 17.3, 10.0, 7.5 Hz, 1H), 6.15 (dd, J = 2.6, 1.9 Hz, 1H), 5.16 – 5.06 (m, 2H), 4.61 (d, J = 7.4 Hz, 1H), 3.81 (s, 3H).

¹³C NMR (126 MHz, $CDCl_3$) δ 158.2, 141.7, 140.8, 136.3, 129.6, 129.4, 128.9, 125.4, 120.2, 119.4, 117.3, 114.8, 113.9, 110.9, 55.4, 47.7.

HRMS (ESI) calcd for $C_{20}H_{20}ON$ $[M+H]^+$: 290.15394, found: 290.15333.

Synthesis of 3-(1-(4-Methoxyphenyl)allyl)-1-phenylpyrrolidine (11) (SGS-6-67)




The following reaction was based on a literature procedure.¹³ A reaction tube equipped with a magnetic stir bar was capped with a Teflon/silicone septum screw cap and flame dried under vacuum. **3fc** (64.3 mg, 0.2 mmol, 1.0 equiv), is dissolved in anhydrous THF (1.0 mL). $LiAlH_4$ (2.7 mg, 0.012 mmol, 5 equiv) was added into the reaction tube in one portion. The reaction tube sealed and stirred at 50 °C, 48 h. The reaction is quenched with water at 0 °C. The crude reaction mixture is extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated. The crude reaction mixture was purified by flash chromatography (hexanes/ethyl acetate = 5:1) to give the pure product **11** as a clear oil (21.5 mg, 37% yield, 5.0:1 d.r.).

¹H NMR (601 MHz, $CDCl_3$) δ 7.24 – 7.19 (m, 2H^{*}), 7.18 – 7.14 (m, 2H[']), 7.14 – 7.10 (m, 2H^{*}+2H[']), 6.89 – 6.83 (m, 2H^{*}+2H[']), 6.65 (t, J = 7.3 Hz, 1H^{*}), 6.61 (t, J = 7.3 Hz, 1H[']), 6.55 (d, J = 8.0 Hz, 2H^{*}), 6.44 (d, J = 8.0 Hz, 2H[']), 6.04 – 5.94 (m, 1H^{*}+1H[']), 5.11 – 4.99 (m, 2H^{*}+2H[']), 3.79 (s, 3H[']), 3.79 (s, 3H^{*}), 3.46 (dd, J = 9.1, 7.6 Hz, 1H^{*}), 3.39 (td, J = 8.8, 2.8 Hz, 1H[']), 3.35 – 3.27 (m, 1H^{*}+1H[']), 3.23 – 3.17 (m, 1H^{*}), 3.14 – 3.04 (m, 2H^{*}+2H[']), 2.83 (t, J = 8.8 Hz, 1H[']), 2.68 – 2.56 (m, 1H^{*}+1H[']), 2.21 (dtd, J = 9.4, 6.7, 2.7 Hz, 1H[']), 1.86 – 1.73 (m, 1H^{*}+1H[']), 1.57 (dq, J = 12.4, 8.8 Hz, 1H^{*}+1H[']).

¹³C NMR (151 MHz, CDCl₃) δ 158.3, 158.3, 148.0, 147.9, 141.2₂, 141.1₇, 135.5, 135.4, 129.3, 129.2, 128.7, 128.6, 115.6₁, 115.5₇, 114.9, 114.8, 114.1₉, 114.1₆, 111.6₁, 111.5₇, 55.4, 54.1₇, 54.1₅, 52.5, 52.4, 47.7, 47.5, 43.6, 43.5, 30.8, 30.5. One peak missing due to overlap.

HRMS (ESI) calcd for C₂₀H₂₄ON [M+H]⁺: 294.18524, found: 294.18549.

Synthesis of 3,4-Diphenylhex-5-enoic acid (12) (SGS-6-83)




The following reaction was based on a literature procedure.¹⁴ *N*-Acyl oxazolidinone **5aa** (67.1 mg, 0.2 mmol, 1.0 equiv), is dissolved in THF:H₂O 3:1 (0.4 mL) in a 5 mL round bottomed flask and cooled to 0 °C. 30% H₂O₂ (0.16 mL, 8.0 equiv) and LiOH (16.8 mg, 2.0 equiv) are sequentially added and the reaction vessel is allowed to warm to room temperature and stirred for 18 h. The peroxide is quenched by the addition of saturated aqueous Na₂SO₃, and the mixture is acidified to pH 1-2 with 6 M HCl. The crude reaction mixture is extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated. The crude reaction mixture was purified by flash chromatography (hexanes/ethyl acetate = 3:1) to give the pure product **12** as a clear oil (51.3 mg, 96% yield, 1:2.2 d.r.)

¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.24 (m, 3H*+3H'), 7.24 – 7.07 (m, 6H*+5H'), 7.05 (t, *J* = 6.8 Hz, 2H'), 6.99 – 6.93 (m, 1H*), 6.09 – 6.00 (m, 1H'), 5.84 – 5.74 (m, 1H*), 5.21 – 5.06 (m, 2H'), 4.91 – 4.70 (m, 2H*), 3.53 – 3.38 (m, 2H*+2H'), 2.98 – 2.92 (m, 1H'), 2.67 – 2.59 (m, 1H'), 2.58 – 2.46 (m, 2H*). Carboxylic acid proton was not observed.

¹³C NMR (126 MHz, CDCl₃) δ 177.5, 177.2, 142.3, 142.1, 141.5, 140.0, 139.3, 128.8, 128.6, 128.4, 128.3, 128.1, 128.1, 126.9, 126.6, 126.3, 116.8, 116.5, 57.2, 55.8, 47.2, 46.7, 39.1₄, 39.1₀.

HRMS (ESI) calcd for C₁₈H₁₇O₂ [M-H]⁻: 265.12231, found: 265.12271.

Synthesis of Prop-2-yn-1-yl 4-(2-bromophenyl)-3-(4-chlorophenyl)hex-5-enoate (13) (SGS-7-4)



The following reaction was based on a literature procedure.¹⁵ A reaction tube equipped with a magnetic stir bar was capped with a Teflon/silicone septum screw cap was flame dried under vacuum. Yb(OTf)₃ (6.2 mg, 10 mol %) was added and the reaction tube was purged with nitrogen. Propargyl alcohol (680 μL) was added to the reaction tube and the catalyst solution was heated to 60 °C for 30 minutes. The reaction vial was removed from the heat for 5 minutes and **5bg** (44.8 mg, 0.100 mmol) dissolved in propargyl alcohol (680 μL) was added. The reaction vial was stirred at 80 °C for 22 hours. The reaction mixture was then cooled, filtered through a silica plug, and the crude reaction mixture was purified by flash chromatography (hexanes/ethyl acetate = 3:1) to give the pure product **13** as a clear oil (37.6 mg, 90% yield, 1:2.5 d.r.).


¹H NMR (500 MHz, CDCl₃) δ 7.60 (dd, *J* = 8.0, 1.0 Hz, 1H*), 7.37 (dd, *J* = 8.0, 0.9 Hz, 1H'), 7.31 – 7.02 (m, 7H*+6H'), 6.94 – 6.90 (m, 1H'), 5.90 (dt, *J* = 17.0, 9.7 Hz, 1H'), 5.72 (ddd, *J* = 17.1, 10.2, 8.3 Hz, 1H*), 5.33 – 5.11 (m, 2H'), 4.89 (dd, *J* = 37.5, 13.6 Hz, 2H*), 4.59 – 4.34 (m, 2H*+2H'), 4.17 (t, *J* = 9.3 Hz, 1H*+1H'), 3.61 (dt, *J* = 10.3, 5.1 Hz, 1H'), 3.50 (td, *J* = 10.4, 4.6 Hz, 1H*), 3.01 (dd, *J* = 15.9, 4.7

Hz, 1H'), 2.68 – 2.60 (m, 1H*+1H'), 2.50 (dd, $J = 15.8, 4.7$ Hz, 1H*), 2.40 (t, $J = 2.4$ Hz, 1H'), 2.37 (t, $J = 2.4$ Hz, 1H*).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 171.3, 171.1, 141.2, 140.9, 139.8, 139.7, 138.5, 137.7, 133.4, 133.2, 132.8, 132.4, 130.0, 129.6, 129.1, 128.9, 128.7, 128.4, 128.4, 128.0, 127.9, 127.6, 125.4, 118.0, 117.7, 77.5₄, 77.4₃, 74.9₆, 74.9₂, 54.0, 53.2, 52.1, 52.0, 46.6, 45.4, 39.6, 38.9.

HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{19}\text{O}_2\text{BrCl}$ $[\text{M}+\text{H}]^+$: 417.02515, found: 417.02509.

Synthesis of 2-(2,5-Diphenylhepta-1,6-dien-4-yl)isoindoline-1,3-dione (**S1**) (SGS-6-79)




The following reaction was based on a literature procedure.¹⁶ A flame dried round bottom flask with stir bar was transferred into the glove box. Methyltriphenylphosphonium bromide (160.8 mg, 0.45 mmol, 1.5 equiv) and potassium tert-butoxide (50.5 mg, 0.45 mmol, 1.5 equiv) are transferred into the flask and subsequently dissolved in anhydrous THF (1.0 mL) at room temperature. The resulting yellow solution was stirred at rt for 1 hr. **7aa** (118.6 mg, 0.3 mmol, 1.0 equiv) is added to the reaction mixture. The flask was sealed, removed from the glove box, and stirred at rt for 16 hours. The reaction is quenched by the addition of water and ethyl acetate. The crude reaction mixture is extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over MgSO_4 , and evaporated under reduced pressure. The crude product was purified by flash chromatography (hexanes/ethyl ether = 100:1) to give the pure product **S1** as a clear oil (55.0 mg, 47% yield, 2.2:1 d.r.).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.79 – 7.46 (m, 4H*+4H'), 7.40 (t, $J = 7.4$ Hz, 2H*), 7.35 (d, $J = 7.0$ Hz, 2H*), 7.31 (t, $J = 7.2$ Hz, 1H*), 7.25 – 6.94 (m, 5H*+10H'), 6.04 (dt, $J = 17.0, 9.7$ Hz, 1H'), 5.82 (dt, $J = 16.9, 9.8$ Hz, 1H*), 5.39 – 4.76 (m, 4H*+4H'), 4.57 (td, $J = 11.6, 3.0$ Hz, 1H*+1H'), 4.26 – 4.20 (m, 1H'), 4.19 – 4.12 (m, 1H*), 3.40 – 3.19 (m, 1H*+2H'), 2.63 (dd, $J = 14.6, 2.0$ Hz, 1H*).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 146.3, 146.0, 141.5, 141.1, 140.7, 140.2, 139.6, 139.0, 133.8, 133.5, 129.2, 128.5, 128.4, 128.3, 128.1, 127.6, 127.5₃, 127.5₁, 127.3, 126.8, 126.4, 126.3, 123.4, 122.9, 117.6, 116.7, 115.6, 115.2, 55.1, 54.4, 53.6, 53.5, 36.2, 35.3. Two peaks missing due to overlap. The broad phthalimide carbonyl peaks were not resolved from baseline.

HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{24}\text{O}_2\text{N}$ $[\text{M}+\text{H}]^+$: 394.18016, found: 394.18021.

Synthesis of 2-(2,4-Diphenylcyclopent-3-en-1-yl)isoindoline-1,3-dione (**14**) (SGS-6-80)



The following reaction was based on a literature procedure.¹⁷ A reaction tube equipped with a magnetic stir bar was capped with a Teflon/silicone septum screw cap and flame dried under vacuum. **S1** (39.3 mg, 0.1 mmol, 1.0 equiv), Grubb's second generation catalyst (8.5 mg, 0.01 mmol, 10% mol), and anhydrous DCE (5 mL) were added into the reaction tube in the glovebox. The reaction tube was sealed, removed from the glove box, and was stirred for 18 h at 80 °C. The reaction mixture was cooled to room

temperature and filtered through a plug of silica gel and washed with CH₂Cl₂ (ca. 30 mL). The crude product was purified by flash chromatography (hexanes/ethyl ether = 20:1) to give the pure product **14** as a yellow oil (12.0 mg, 33% yield, 1:1.6 dr).

¹H NMR (500 MHz, CDCl₃) δ 7.85 – 7.80 (m, 2H*), 7.74 – 7.69 (m, 2H*), 7.62 – 7.55 (m, 1H*), 7.48 (d, *J* = 7.7 Hz, 2H*), 7.42 – 7.19 (m, 7H*+9H'), 7.12 (d, *J* = 7.7 Hz, 2H'), 7.05 (t, *J* = 7.5 Hz, 2H'), 6.98 (t, *J* = 7.3 Hz, 1H'),

6.36 (d, *J* = 2.0 Hz, 1H'), 6.27 (s, 1H*), 5.40 (td, *J* = 9.1, 6.2 Hz, 1H'), 4.96 (q, *J* = 8.8 Hz, 1H*), 4.82 – 4.77 (m, 1H*), 4.50 (d, *J* = 8.8 Hz, 1H'), 3.97 (ddt, *J* = 16.1, 6.1, 1.9 Hz, 1H'), 3.46 – 3.38 (m, 1H*), 3.17 – 3.07 (m, 1H*+1H').

¹³C NMR (126 MHz, CDCl₃) δ 168.5, 168.4, 142.8, 141.3, 135.8, 134.1, 133.7, 132.1, 128.9, 128.9, 128.7, 128.6, 128.0, 127.8₇, 127.8₀, 127.6, 127.2, 127.0, 126.0, 125.8, 123.4, 122.8, 58.4, 55.1, 54.2, 54.1, 36.8, 34.7.

HRMS (ESI) calcd for C₂₅H₂₀O₂N [M+H]⁺: 366.14886, found: 366.14940.

4. Assignment of diastereomers

4.1 Assignment for succinimide products **3** by X-ray crystallography

A sample **3fc** was crystallized from previously isolated material using slow evaporation out of dichloromethane and hexanes to achieve crystals with further diastereomeric enrichment.




Figure S1: Structure of diastereomerically enriched **3fc**. Ellipsoid contour probability is set at 50%

The observed relative configuration of the major product is consistent with a Mukaiyama-type open transition state, in which additive coordinated to the γ carbon of the Michael acceptor is close enough to the incoming allyliron to have an effect on the diastereoselectivity of the allylation product.




Figure S2: Postulated open transition state and anticipated stereochemical outcome

4.2 Assignment for β -aminoketones products **7** and **9** by nOe experiments and multiplet analysis

Comparison of coupling constants and nuclear Overhauser effect experiments were conducted on the cyclic derivative **14** and the *anti*-diastereomer was determined to be the major product.




Figure S3: Derivatization reactions and observed stereochemical outcomes

The major product of the Wittig reaction was identified as the major product of the iron-catalyzed reaction based on comparison of coupling constants for the alkene protons at 6.07 (minor) and 5.92 (major), which remain at (dt, $J = 16.9, 9.8$ Hz) and (dt, $J = 16.9, 9.9$ Hz), respectively. The major product of olefin metathesis was identified as the major product of the Wittig reaction by integration comparison.




Figure S4: ^1H NMR of **14** showing protons H_a , H_b , H_A , and H_B




Figure S5: NOE irradiation at protons H_b , and H_B overlapped spectra




Figure S6: NOE irradiation at protons H_a and H_A overlapped spectra





Figure S7: Crude NMR spectrum of transformation showing original diastereomeric ratio before enrichment on silica. The diastereomeric ratio is consistent with the crude spectra of the Michael addition.

Comparison of *syn*- and *anti*-configurations by DFT optimized geometry shows dihedral angles of which are consistent with a quartet splitting pattern for the *anti*-isomer, and a triplet of doublets for the *syn*-isomer.



Entry	Chemical Shift (experimental)	Coupling Constants (experimental)	Dihedral Angles (DFT)	Coupling Constants (Karplus curve prediction based on cyclopentane)
<i>syn</i>	5.45	9.1, 9.1, 6.2	13.5, 6.4, 112.4	11, 11, 4
<i>anti</i>	4.99	8.9, 8.9, 8.9	152.6, 155.2, 32.4	10.5, 10.5, 9

Karplus curve predictions were based on cyclopentane Karplus curve data from professor Hans J. Reich's NMR spectroscopy collection: <https://organicchemistrydata.org/hansreich/resources/nmr/?page=05-hmr-05-3j%2F#05-hmr-05-3j-cyclopentane> Accessed 4/12/2024






Figure S8: Comparison of dihedral angles for *syn*- and *anti*-configurations by DFT (B3LYP/6-31G) optimized geometry

4.3 Assignment for oxazolidinone products **5** by chemical correlation with known diol



A sample of **5aa** was reduced to the aldehyde with LAH and subsequently transformed into diol with Borane THF to give a diastereomeric mixture of 3,4-diphenylhexane-1,6-diol.

This was compared to published values in N. Kise, K. Iwasaki, N. Tokieda, and N. Ueda, *Org. Lett.*, 2001, **3**, 3241-3244.



3,4-diphenylhex-5-enal (**S2**): (SGS-7-22)


5aa (0.19mmol, 1.0 equiv, 2.1:1 dr) is placed in a flame dried round bottom flask under nitrogen and dissolved in dry THF (0.2 M). Lithium aluminum hydride (14.4 mg, 2.0 equiv) is added at 0 °C and the reaction mixture is allowed to warm to room temperature and is stirred for 24 h or until consumption of

the starting material. The reaction mixture is then cooled to 0 °C and treated with water, extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated *in vacuo*. ¹H NMR analysis of the crude mixture showed 1:2.2 dr. Purification by preparatory TLC in 2:1 hexanes:ethyl acetate gave pure 3,4-diphenylhex-5-enal as a white solid (25.0 mg, 50% yield, 2.2:1 dr).

¹H NMR (400 MHz, CDCl₃) δ 9.65 – 9.61 (m, 1H'), 9.45 – 9.42 (m, 1H*), 7.36 – 7.10 (m, 8H*+8H'), 7.09 – 7.03 (m, 2H'), 7.02 – 6.95 (m, 2H*), 6.04 (dt, *J* = 16.9, 9.8 Hz, 1H'), 5.90 – 5.74 (m, 1H*), 5.17 (dd, *J* = 16.9, 0.8 Hz, 1H'), 5.12 (dd, *J* = 10.1, 1.5 Hz, 1H'), 4.89 (d, *J* = 1.0 Hz, 1H*), 4.87 (d, *J* = 0.7 Hz, 1H*), 4.76 (dd, *J* = 9.6, 8.5 Hz, 1H), 3.64 – 3.42 (m, 2H*+2H'), 3.00 (ddd, *J* = 17.1, 5.0, 1.4 Hz, 1H'), 2.79 (ddd, *J* = 17.1, 9.2, 2.2 Hz, 1H'), 2.68 (ddd, *J* = 17.0, 9.1, 2.3 Hz, 1H*), 2.56 (ddd, *J* = 17.1, 4.6, 1.4 Hz, 1H*).

¹³C NMR (101 MHz, CDCl₃) δ 201.8, 201.5, 142.2, 142.0, 141.8, 141.7, 140.2, 139.2, 128.9, 128.6, 128.4, 128.3, 128.1, 127.0₄, 126.9₉, 126.6, 126.4, 116.8, 116.6, 57.5, 56.0, 48.6, 48.5, 45.7, 45.2. Three peaks missing due to overlap.

HRMS (ESI) calcd for C₁₈H₁₉O [M+H]⁺: 251.14304, found: 251.14280.



3,4-diphenylhexane-1,6-diol: (SGS-7-34)

3,4-diphenylhex-5-enal (0.07mmol, 1.0 equiv, 2.2:1 dr) is placed in a flame dried round bottom flask under nitrogen. Borane THF (0.2 mL, 3.0 equiv, 1 M in THF) is added to the neat material at room temperature. The reaction mixture is stirred for 2 h, then cooled to 0 °C and treated with water (0.14 mL, 2 mL/mmol) followed by sodium perborate (34.9 mg, 5 equiv). The reaction mixture is allowed to gradually return to room temperature over 18 h. The crude reaction mixture is then extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated *in vacuo*. ¹H NMR analysis of the crude mixture showed 1:2.7 dr. Purification by preparatory TLC in 3:1 hexanes:ethyl acetate gave pure 3,4-diphenylhexane-1,6-diol as a white solid with diastereomers separated.





Figure S9: Crude NMR spectrum of transformation showing diastereomeric ratio before separation of diastereomers. The diastereomeric ratio is consistent with the crude spectra of the Michael addition.




meso-3,4-diphenylhexane-1,6-diol (S3): (SGS-7-34-P3)

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.37 (t, $J = 7.6$ Hz, 4H), 7.28 – 7.26 (m, 6H), 3.36 – 3.30 (m, 2H), 3.23 (dt, $J = 10.5, 7.4$ Hz, 2H), 2.95 – 2.88 (m, 2H), 1.68 – 1.62 (m, 4H), 1.59 (s broad, 2H).

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 143.6, 128.9, 128.4, 126.8, 61.3, 49.0, 37.6.

HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{O}_2$ $[\text{M}+\text{H}]^+$: 271.16926, found: 271.16881.



(3R,4R)-3,4-diphenylhexane-1,6-diol and (3S,4S)-3,4-diphenylhexane-1,6-diol (S4): (SGS-7-34-P4)

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.17 – 7.08 (m, 6H), 6.90 (d, $J = 6.9$ Hz, 4H), 3.53 (ddd, $J = 10.8, 7.1, 4.8$ Hz, 1H), 3.40 (ddd, $J = 10.6, 7.9, 6.5$ Hz, 1H), 3.07 – 2.98 (m, 2H), δ 2.18 (dtd, $J = 10.8, 7.8, 3.6$ Hz, 1H), 1.92 – 1.81 (m, 2H), 1.55 (s broad, 2H).

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 142.0, 129.0, 128.0, 126.4, 61.4, 48.1, 36.1.


HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{O}_2$ $[\text{M}+\text{H}]^+$: 271.16926, found: 271.16897.

This spectra data matches literature the values (N. Kise, K. Iwasaki, N. Tokieda, and N. Ueda, *Org. Lett.*, 2001, 3, 3241-3244). $^1\text{H NMR}$ (270 MHz, CDCl_3) δ 7.05-7.17 (m, 6H), 6.87-6.92 (m, 4H), 3.48-3.59 (m, 2H), 3.34-3.46 (m, 2H), 2.98-3.07 (m, 2H), 2.12-2.24 (m, 2H), 1.80-1.93 (m, 2H), 1.43 (brs, 2H). $^{13}\text{C NMR}$ (CDCl_3) δ 147.76, 128.75, 127.58, 125.94, 60.86, 47.63, 35.94.

5. Reaction optimization

5.1 Optimization of Maleimide Michael Acceptors


Table S1. Reaction discovery and Lewis acid investigation



Entry	Lewis Acid	Lewis Acid Equiv	Base Equiv	Time (hr)	Temp. (°C)	NMR Maleimide (%)	NMR Yield (%) ^a
SGS-5-94-1	TIPSOTf	1.5	2.5	18	80	0	<10
SGS-5-94-2	TIPSOTf	2.2	2.5	18	60	0	<10
SGS-5-136	TMSTOf	2.5	3	18	60	0	0
SGS-5-101-1	BF ₃ •Et ₂ O	2	3	4	80	24	28
SGS-5-101-2	BF ₃ •Et ₂ O	2	3	4	50	57	27
SGS-5-137-1	BF ₃ •Et ₂ O	3	4	18	60	0	29
SGS-5-137-2	BF ₃ •Et ₂ O	6	4	18	60	0	<10
SGS-5-141	BF ₃ •Et ₂ O	3	4	3	60	15	30

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine.

Table S2: Exploration to find significant parameters




Entry	Variation from Standard Conditions	NMR Maleimide SM (%)	NMR Yield (%) ^a
SGS-5-142-1	100 °C	0	19
SGS-5-142-2	0.5 M DCE	12	15
SGS-5-142-3	0.35 equiv LiNTf ₂	0	37
SGS-5-142-4	0.6 equiv LiNTf ₂	0	32

SGS-5-142-5	1.0 equiv LiNTf ₂	0	38
SGS-5-142-6	0.1 equiv LiNTf ₂	trace	23

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine.


Table S3: Base optimization



Entry	Base	NMR Maleimide SM (%)	NMR Yield (%) ^a
SGS-5-143-1	TMPH	0	0
SGS-5-143-2	4-Cl-Lutidine	0	47
SGS-5-143-3	Lutidine	0	40
SGS-5-143-4	4-Br-Lutidine	0	44
SGS-7-15	2,3,5,6-Tetramethylpyrazine	0	16 (5.2:1 dr)


^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. TMPH = 2,2,6,6-tetramethylpiperidine.

Table S4: Temperature optimization




Entry	Temperature (°C)	NMR Maleimide SM (%)	NMR Yield (%) ^a
SGS-5-143-2	60	0	47
SGS-5-159	50	0	54
SGS-5-147-1	40	0	64
SGS-5-148-1	30	30	37
SGS-5-148-2	RT	24	23

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard.

Table S5: Stoichiometry optimization

Entry	Ratio (Lewis Acid/Base)	NMR Maleimide SM (%)	NMR Yield (%) ^a
SGS-5-147-1	3/4	0	64
SGS-5-158-1	3/3	0	45
SGS-5-158-2	2.2/4	0	69
SGS-5-158-3	2.2/3	0	57
SGS-5-158-5	2.2/5	0	70
SGS-5-158-6B	1.0/4	0	71
SGS-5-158-4	1.5/4	0	80
SGS-5-158-7	1.5/4 + 8hr run time	9	53


^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard.

Table S6: Diastereomeric ratio optimization

Entry	Variation from Standard Conditions	NMR Maleimide SM (%)	NMR Yield (%) ^a	d.r.
SGS-6-11-1	none	0	83	3.7:1
SGS-6-11-2	35 °C	0	82	3.8:1
SGS-6-11-3	30 °C	0	55	4.2:1
SGS-6-11-5	0.6 equiv LiNTf ₂	5	66	4.0:1
SGS-6-11-6	0.2 equiv LiNTf ₂	4	74	3.9:1

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard.


Table S7: Additive optimization for diastereomeric ratio



Entry	Additive	NMR Maleimide SM (%)	NMR Yield (%) ^a	d.r.
SGS-6-11-4	CuNTf ₂	61	17	3.8:1
SGS-5-185-1	Ca(NTf ₂) ₂	86	<i>trace</i>	-
SGS-5-185-2	Mg(NTf ₂) ₂	21	75	6.4:1
SGS-5-185-3	Zn(NTf ₂) ₂	0	19	1.7:1
SGS-5-185-4	Zn(OTf) ₂	60	20	5.7:1
SGS-5-185-5	LiOTf	58	29	6.4:1
SGS-5-185-6	AgNTf ₂	0	77	7.3:1
SGS-5-187-1	Yb(OTf) ₃	80	12	-
SGS-5-187-2	Bi(OTf) ₃	80	<10	-
SGS-5-187-4	AgOTf	89	0	-
SGS-5-187-5	Eu(OTf) ₃	96	0	-
SGS-5-187-6	Er(OTf) ₃	87	<10	-
SGS-7-14-1	Tritylium tetrafluoroborate	43	12	5.8:1
SGS-7-14-2	Triphenyl borane	40	10	6.0:1

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard.

Table S8: Exploration with silver bistriflimide additive




Entry	Variation from Standard Conditions	NMR Maleimide SM (%)	NMR Yield (%) ^a	d.r.
SGS-5-185-6	none	0	77	7.3:1

SGS-5-188-8	0.5 equiv additive	8	63	6.8:1
SGS-5-188-7	0.3 equiv additive	11	67	6.3:1
SGS-5-188-5	No additive	41	25	6.4:1
SGS-5-189-1	No BF ₃ •Et ₂ O	88	0	-
SGS-5-188-9	No Catalyst	100	0	-
SGS-5-188-6	Toluene as solvent	8	75	7.2:1
SGS-5-192	Toluene as solvent + 24 hr reaction	0	(89) ^b	7.6:1
SGS-7-1	No Additive + Toluene as solvent + 24 hr reaction	67	9	6.3:1
SGS-7-7	Toluene as solvent + 24 hr reaction + lutidine as base	61	27	6.7:1
SGS-7-18	Pentaethyl substituted cyclopentadiene ligand	21	24	14.3:1

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. ^bIsolated Yield.

5.2 Optimization of *N*-Acyl-Oxazolidinone Michael Acceptors

Table S9. Reaction discovery and Lewis acid investigation




Entry	Additive (20%)	Ratio (alkene/Co-Lewis Acids/Base)	Temp. (°C)	NMR SM (%)	NMR Yield (%) ^a	d.r.
SGS-4-96-1	None	2/2/3	80	19	17	2.4:1
SGS-4-96-2	Yb(OTf) ₃	2/2/3	80	30	19	2.4:1
SGS-4-96-3	CuOTf	2/2/3	80	23	14	2.0:1
SGS-5-1-1	Yb(OTf) ₃	3/2/3	80	23	27	3.2:1
SGS-5-1-2	Yb(OTf) ₃	2/2/4	80	23	16	2.0:1
SGS-5-1-3	Yb(OTf) ₃	2/1.2/4	80	43	7	1.4:1

SGS-5-1-4	Yb(OTf) ₃	2/1.2/3	80	47	14	2.2:1
SGS-5-1-5A	Yb(OTf) ₃	2/1.2/2	80	30	16	2.8:1
SGS-5-1-5B	Yb(OTf) ₃	3/1.2/2	80	51	19	3.2:1
SGS-5-1-5C	Yb(OTf) ₃	2/1.2/2	100	45	11	2.3:1

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine.

Table S10. Control reactions and comparison of Lewis acids needed




Entry	BF ₃ ·Et ₂ O	TMSOTf	Additive	NMR SM (%)	NMR Yield (%) ^a	d.r.
SGS-5-1-1	Y	Y	Y	23	27	2.3:1
SGS-5-16-1	Y	-	-	24	<10	-
SGS-5-16-2	Y	-	Y	58	0	-
SGS-4-96-1	Y	Y	-	19	17	2.4:1
SGS-5-16-3	-	Y	-	79	0	-
SGS-5-16-4	-	Y	Y	73	0	-

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine.

The results of a control reaction indicated that BF₃·Et₂O alone is sufficient for the reaction, but the addition of TMSOTf and Additive increase the yield. Reactions tried with the stronger base 2,4,6-trimethyl pyridine gave no product, presumably because it ties up more of the available Lewis acid. Together, these indicate that a significant increase in the amount of Lewis acid is necessary.

Table S11. Increasing free Lewis acid



Entry	Ratio (BF ₃ ·Et ₂ O/Base)	Base	NMR SM (%)	NMR Yield (%) ^a	d.r.
-------	---	------	------------	----------------------------	------

SGS-5-19-1	3/3	4-Cl-Lutidine	19	41	2.6:1
SGS-5-19-2	2/2	Collidine	48	21	3.9:1
SGS-5-19-3	3/3	Collidine	31	19	6.1:1
SGS-5-19-4	4/3	Collidine	47	29	6.6:1
SGS-5-21-1	4/3	4-Cl-Lutidine	4	39	2.1:1
SGS-5-21-2	3/2	4-Cl-Lutidine	44	trace	-
SGS-5-21-3	4/2	Collidine	39	<10%	-
SGS-5-24-1	3/2	Collidine	20	21	-
SGS-5-24-2	3/1.2	Collidine	35	0	-
SGS-5-24-3	3/1.2	Collidine	63	0	-
SGS-5-24-4	5/3	Collidine	9	35	2.4:1
SGS-5-36-1	5/3	4-Cl-Lutidine	48	46	3.8:1

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine.

These results validate the hypothesis that significant free BF₃•Et₂O is needed in the reaction. Good yields are observed with equivalents of Lewis acid greater than the equivalents of base, which was unprecedented for our group's explorations of cyclopentadienyldicarbonyl iron complex catalysis.

Table S12. Optimization of Additive

Entry	Additive	Additive Equivalents	NMR SM (%)	NMR Yield (%) ^a	d.r.
SGS-5-39-4	LiNTf ₂	0.2	18	67	2.5:1
SGS-5-39-3	Cu(NTf ₂) ₂	0.2	34	42	2.8:1
SGS-5-39-5	Yb(OTf) ₃	0.2	40	54	2.7:1
SGS-5-39-6	Zn(OTf) ₂	0.2	30	57	2.8:1
SGS-6-21	LiNTf ₂	1.0	0	85 (88%) ^b	2.2:1


^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. ^bIsolated Yield.

Table S13. Control Experiments

Entry	BF ₃ ·Et ₂ O Equivalents	Base Equivalents	NMR SM (%)	NMR Yield (%) ^a	d.r.
SGS-7-6-1	1.5	4	54	trace	-
SGS-7-6-2	5.0	3	0	19	1.4:1

5.3 Optimization of Phthalimide Michael Acceptors


Table S14. Optimization for substituted allylbenzene derivatives



Entry	Ratio (SiR ₃ /Base/additive)	Silyl Triflate	Temp.	NMR SM (%)	NMR Yield (%) ^a
SGS-5-114-1	1.5/2.0/0.6	TIPSOTf	80	41	29
SGS-5-114-2	1.5/2.0/0.6	TMSOTf	80	23	18
SGS-5-144-2	2.5/3.0/0.6	TIPSOTf	80	0	90 (93%) ^b
SGS-5-144-1	2.5/3.0/0.6	TMSOTf	80	0	37
SGS-5-144-3	2.5/3.0/0.3	TIPSOTf	80	0	73
SGS-5-164-1	2.5/3.0/0.6	TIPSOTf	60	0	85

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. ^bIsolated Yield.

Table S15. Optimization for unactivated alkene substrates




Entry	Temp.	Base	Base (equiv)	NMR Yield (%) ^a
SGS-6-3-1	80	Collidine	3	<20

SGS-6-3-2	90	Collidine	3	30
SGS-6-3-3	80	Collidine	4	44
SGS-6-3-4	80	TMPH	3	45
SGS-6-3-5	80	TMPH	4	79 (66) ^b

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. ^bIsolated Yield. TMPH = 2,2,6,6-tetramethylpiperidine.

5.4 Optimization of Sulfonamide Michael Acceptors

Table S16. Optimization of reaction



Entry	Solvent	Temp	TIPSOTf equiv	Base equiv	NMR Yield (%)	NO ₂	SM (%)
SGS-5-146-1	DCE	60	1.5	2.5 (Collidine)	43	- <i>p</i>	0
SGS-5-168-4	DCE	60	1.5	2.5 (4-Cl-Lutidine)	18	- <i>p</i>	10
SGS-5-146-2	DCE	60	2.5	3.0 (Collidine)	43	- <i>p</i>	0
SGS-5-168-1	DCE	80	2.5	3.0 (Collidine)	22	- <i>p</i>	0
SGS-5-146-3	PhCl	60	2.5	3.0 (Collidine)	31	- <i>p</i>	7
SGS-5-146-5	DCE	60 (8 h)	2.5	3.0 (Collidine)	22	- <i>p</i>	20
SGS-5-168-3	DCE	60	2.5	2.5 (Collidine)	46	- <i>p</i>	trace
SGS-5-168-6	DCE	50	2.5	2.5 (Collidine)	18	- <i>p</i>	14
SGS-5-168-5	DCE	60	2.5	2.5 (4-Cl-Lutidine)	35	- <i>p</i>	0
SGS-5-168-7	DCE	60	2.5	2.5 (TMPH)	42	- <i>p</i>	trace

SGS-5-168-8	DCE	60	2.5+0.6 equiv LiNTf ₂	2.5 (Collidine)	67	- <i>p</i>	0
SGS-5-172-1	DCE	60	2.0+0.6 equiv LiNTf ₂	2.0 (Collidine)	60	- <i>p</i>	0
SGS-5-172-2	DCE	60	2.5+0.8 equiv LiNTf ₂	2.5 (Collidine)	67	- <i>p</i>	0
SGS-5-184-1	DCE	60	2.5+0.6 equiv LiNTf ₂	2.5 (Collidine)	84 (72) ^b	- <i>o</i>	0
SGS-5-184-2	DCE	60	2.5+0.6 equiv LiNTf ₂	3.5 (Collidine)	76	- <i>o</i>	0

^aYields determined by ¹H NMR using 2,4-dinitrotoluene as the internal standard. Collidine = 2,4,6-trimethyl pyridine. TMPH = 2,2,6,6-tetramethylpiperidine.

6. Unsuccessful substrates

Unsuccessful Michael Acceptors:





Figure S10: Unsuccessful nitrogen-containing Michael acceptors


7. Copies of NMR spectra of products and substrates

7.1 NMR spectra: Maleimide Scope



SGS-5-192




SGS-5-192 H




SGS-5-192 H




3aa
¹H NMR
 500 MHz, CDCl₃




3aa
¹³C NMR
126 MHz, CDCl₃








3ba
¹H NMR
 500 MHz, CDCl₃




SGS-6-34 H




SGS-6-34 H




3ba
¹H NMR
 500 MHz, CDCl₃




3ba
¹³C NMR
126 MHz, CDCl₃






3ca
¹H NMR
 500 MHz, CDCl₃





SGS-6-35 H




SGS-6-35 H


SGS-6-35 H




3a
¹H NMR
 500 MHz, CDCl₃




3ca
¹³C NMR
 126 MHz, CDCl₃




SGS-6-24 H




SGS-6-24 H






3da
¹³C NMR
 126 MHz, CDCl₃




SGS-6-44 H




SG5-6-44 H


SG5-6-44 H




3ea
 ^1H NMR
 500 MHz, CDCl_3





SG5-6-44 H









3ea
¹³C NMR
 126 MHz, CDCl₃









3fa
 ^1H NMR
 500 MHz, CDCl_3








3ga

¹H NMR
500 MHz, CDCl₃












3ha
¹³C NMR
 151 MHz, CDCl₃



SGS-6-40 F




3ha
¹⁹F NMR
471 MHz, CDCl₃




S80

SGS-6-59 H




3ja


¹H NMR
500 MHz, CDCl₃




S81



3ja
¹³C NMR
 126 MHz, CDCl₃



SGS-6-59 F





3ja

¹⁹F NMR
471 MHz, CDCl₃


-62.75
-62.78


SGS-6-59 F

-62.75
-62.78





S83






3ka
¹³C NMR
126 MHz, CDCl₃






3la
¹H NMR
 500 MHz, CDCl₃





SGS-6-38 H




SGS-6-38 H

SGS-6-38 H

**3la**


¹H NMR
500 MHz, CDCl₃


SGS-6-38 C




3a


¹³C NMR
126 MHz, CDCl₃









3ab
¹³C NMR
 126 MHz, CDCl₃




SGS-6-56 F





3ab
¹⁹F NMR
471 MHz, CDCl₃







3ac
 ^1H NMR
500 MHz, CDCl_3






3ac
¹³C NMR
 126 MHz, CDCl₃







SGS-6-54 C




3ad
¹³C NMR
126 MHz, CDCl₃




SGS-6-54 F






3ad
¹⁹F NMR
471 MHz, CDCl₃




SGS-6-45 H







3ae
 ^1H NMR
 500 MHz, CDCl_3






SGS-6-55 H




3af
¹H NMR
500 MHz, CDCl₃











SGS-6-47 H




3fc

¹H NMR
500 MHz, CDCl₃







3fc
¹H NMR
 500 MHz, CDCl₃




3c
¹³C NMR
126 MHz, CDCl₃




7.2 NMR spectra: Oxazolidinone Scope







5aa

¹³C NMR
126 MHz, CDCl₃




S107




5aa


COSY NMR - aliphatic
500 MHz, CDCl₃


SGS-6-71 H




5ba
¹H NMR
500 MHz, CDCl₃












5ba
COSY NMR - aliphatic
500 MHz, CDCl₃









5bg
 ^1H NMR
 500 MHz, CDCl_3




5bg
¹³C NMR
 126 MHz, CDCl₃



SGS-6-76 (major) H





SGS-6-76 (major) H




SGS-6-76 (major) H




SGS-6-76 (major) H



5ah
 ^1H NMR
 500 MHz, CDCl_3


SGS-6-76 (major) C






5ah
¹H NMR
 500 MHz, CDCl₃


SGS-6-76 (minor) C






5ah
¹³C NMR
126 MHz, CDCl₃



SGS-7-8 H




SGS-7-8 H




5bj
¹H NMR
 400 MHz, CDCl₃

SGS-7-8 C




5bj
¹³C NMR
126 MHz, CDCl₃




7.3 NMR spectra: Phthalimide Scope


SGS-5-144 H





SG5-5-144 H




SG5-5-144 H




SG5-5-144 H


**7aa**

^1H NMR
500 MHz, CDCl_3






**7ae**


$^1\text{H NMR}$
500 MHz, CDCl_3



SG5-6-1-H




7ae
¹H NMR
 500 MHz, CDCl₃




7ae

¹³C NMR

126 MHz, CDCl₃





SGS-6-5 H




SGS-6-5 H


SGS-6-5 H




7ac
¹H NMR
 500 MHz, CDCl₃




7ac
¹³C NMR
 126 MHz, CDCl₃









7ai
¹H NMR
 500 MHz, CDCl₃




SG5-6-6 H






7ai
¹H NMR
 500 MHz, CDCl₃




SGS-6-2 H




S136




7ag
 $^1\text{H NMR}$
 500 MHz, CDCl_3







SG5-6-4 H




SG5-6-4 H




7aj
 ^1H NMR
 500 MHz, CDCl_3


SGS-6-4 C




SGS-6-4 F




7aj
¹⁹F NMR
471 MHz, CDCl₃



SGS-6-3 H





SG5-6-3 H




SG5-6-3 H

SG5-6-3 H




S145


SGS-6-3 C






7ak
¹³C NMR
126 MHz, CDCl₃




SGS-5-23 H





7a
¹H NMR
 500 MHz, CDCl₃


SGS-5-23 C






7al

¹³C NMR


126 MHz, CDCl₃




S149




7am
¹H NMR
 500 MHz, CDCl₃




7am
 ^{13}C NMR
126 MHz, CDCl_3






7an
¹H NMR
 500 MHz, CDCl₃





SG5-6-7 H




SG5-6-7 H


SG5-6-7 H




7an
 ^1H NMR
 500 MHz, CDCl_3




SGS-6-53 H





7ao
¹H NMR
500 MHz, CDCl₃




SG5-6-53 H




SG5-6-53 H




7ao
¹H NMR
 500 MHz, CDCl₃






7ao
¹³C NMR
 126 MHz, CDCl₃




SGS-6-8 H



S159





7ap
 ^1H NMR
 500 MHz, CDCl_3



7ap


COSY NMR - aromatic
500 MHz, CDCl₃









7ap

COSY NMR - aliphatic
500 MHz, CDCl₃











7aq
COSY NMR - aliphatic
500 MHz, CDCl₃




7.4 NMR spectra: Sulfonamide Scope

SGS-5-184 H




9aa



¹H NMR
500 MHz, CDCl₃




SGS-5-184 H







SGS-5-184 H




9aa
¹H NMR
 500 MHz, CDCl₃









9af
 ^1H NMR
 500 MHz, CDCl_3




9af
¹³C NMR
 126 MHz, CDCl₃




SGS-6-19 H



SGS-6-19 C




9ka
¹³C NMR
126 MHz, CDCl₃




S174

SGS-5-168-8 H





S175


SGS-5-168-8 C




9ba
¹³C NMR
126 MHz, CDCl₃









9ca
¹³C NMR
101 MHz, CDCl₃



SGS-6-63 H





SG5-6-63 H




SG5-6-63 H


SG5-6-63 H



9da
¹H NMR
 500 MHz, CDCl₃




SGS-6-63 F



9da


¹⁹F NMR
471 MHz, CDCl₃




S182

7.5 NMR spectra of starting materials


SGS-5-191 H




2g
 ^1H NMR
500 MHz, CDCl_3




SGS-5-191 C




2g
¹³C NMR
126 MHz, CDCl₃




SGS-5-181 H




8a
 $^1\text{H NMR}$
500 MHz, CDCl_3







8a
¹³C NMR
126 MHz, CDCl₃




SGS-5-183 H




8d
¹H NMR
500 MHz, CDCl₃





SGS-5-183 F




8d
¹⁹F NMR
471 MHz, CDCl₃








5ah
 $^1\text{H NMR}$
400 MHz, CDCl_3





7.6 NMR spectra of synthetic application of products

SGS-6-94 H





10
¹H NMR
500 MHz, CDCl₃







10
¹³C NMR
126 MHz, CDCl₃









11
¹³C NMR
126 MHz, CDCl₃




SGS-6-60 H





S195




12
¹³C NMR
126 MHz, CDCl₃





12
COSY NMR – aliphatic region
500 MHz, CDCl₃








13
¹H NMR
500 MHz, CDCl₃






13
¹³C NMR
 126 MHz, CDCl₃









S1
¹H NMR
 500 MHz, CDCl₃




S1
¹³C NMR
126 MHz, CDCl₃








SGS-7-34 (p4) 600
SGS-7-35 (p4) 1H



SGS-7-34 (p4) 600
SGS-7-35 (p4) 13C



8. References

1. Y. Wang, J. Zhu, A. C. Durham, H. Lindberg and Y.-M. Wang, *J. Am. Chem. Soc.*, 2019, **141**, 19594-19599.
2. G. Xu, Y. Yang, Y. Yang, G. Song, S. Li, J. Zhang, W. Yang, L.-L. Wang, Z. Weng and Z. Zuo, *Eur. J. Med. Chem.*, 2020, **191**, 112115.
3. Y. He, W. Li, H. Zhou, G. Zeng, Z. Chen, J.-Y. Ge, N. Lv and J. Chen, *Adv. Synth. Catal.*, 2022, **364**, 3730-3735.
4. X. Li, X. Zhang, F. Zhang, X. Luo and H. Luo, *Adv. Synth. Catal.*, 2022, **364**, 1683-1688.
5. N. M. Nascimento-Júnior, T. C. F. Mendes, D. M. Leal, C. M. N. Corrêa, R. T. Sudo, G. Zapata-Sudo, E. J. Barreiro and C. A. M. Fraga, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 74-77.
6. L. Zhao, Y. Ma, W. Duan, F. He, J. Chen and C. Song, *Org. Lett.*, 2012, **14**, 5780-5783.
7. J.-F. Wang, X. Meng, C.-H. Zhang, C.-M. Yu and B. Mao, *Org. Lett.*, 2020, **22**, 7427-7432.
8. X. Liang, X. Huang, M. Xiong, K. Shen and Y. Pan, *Chem. Commun.*, 2018, **54**, 8403-8406.
9. A. Gómez-Palomino and J. Cornella, *Angew. Chem. Int. Ed.*, 2019, **58**, 18235-18239.
10. S. G. Scrivener, Y. Wang and Y.-M. Wang, *Org. Lett.*, 2023, **25**, 1420-1424.
11. X. Qi, P. Chen and G. Liu, *Angew. Chem. Int. Ed.*, 2017, **56**, 9517-9521.
12. S.-L. Liu, Y. Li, J.-R. Guo, G.-C. Yang, X.-H. Li, J.-F. Gong and M.-P. Song, *Org. Lett.*, 2017, **19**, 4042-4045.
13. L. M. Rice, E. E. Reid and C. H. Grogan, *J. Org. Chem.*, 1954, **19**, 884-893.
14. G. L. Beutner, B. M. Cohen, A. J. DelMonte, D. D. Dixon, K. J. Fraunhoffer, A. W. Glace, E. Lo, J. M. Stevens, D. Vanyo and C. Wilbert, *Org. Process Res. Dev.*, 2019, **23**, 1378-1385.
15. J. M. Stevens, A. C. Parra-Rivera, D. D. Dixon, G. L. Beutner, A. J. DelMonte, D. E. Frantz, J. M. Janey, J. Paulson and M. R. Talley, *J. Org. Chem.*, 2018, **83**, 14245-14261.
16. Z. Zhao, L. Racicot and G. K. Murphy, *Angew. Chem. Int. Ed.*, 2017, **56**, 11620-11623.
17. A. K. Chatterjee, T.-L. Choi, D. P. Sanders and R. H. Grubbs, *J. Am. Chem. Soc.*, 2003, **125**, 11360-11370.